



This is our sixth annual sustainability report, 
and it describes our progress and challenges 
from 1 January 2020 to 31 December 2020, unless 
otherwise stated. The content of this report is based 
on those sustainability focus areas deemed material 
through comprehensive stakeholder engagement 
and analysis. All our business operations 
worldwide are in scope regardless of their 
function, unless otherwise stated.
Online resources 
AstraZeneca Sustainability Data Summary: 
provides performance measures and 
targets with at least three years of data, 
where available, and a United Nations 
Sustainable Development Goals index.
AstraZeneca Sustainability webpages: 
cover additional topics of interest to our 
stakeholders.
Infographics: show our processes 
and practices.
Policies and company standards: state our 
position and guidance on key topics.
2020 Annual Report: includes how 
sustainability is integrated across our 
business model and into risk management.
Disease understanding
Connecting broader omic-technologies 
can identify the more complex and 
transient molecular changes that 
underpin the course of disease. 
AstraZeneca is turning this data into 





We obtained external review of our sustainability performance to validate that we use the same rigour and accuracy as we do with regulated reporting. 
Bureau Veritas has provided independent external assurance for progress on all sustainability targets and all sustainability key performance indicators 
shown in the Sustainability Data Summary. Details are described in the sustainability letter of assurance. Assurance was also provided for select 
sustainability information in the 2020 Annual Report. Assurance is in accordance with the International Standard on Assurance Engagements 3000 
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Message from the CEO
2020 was a year like no other, with COVID-19 
presenting unprecedented challenges for us all. 
I am proud of the fact that, in the face of the 
pandemic, AstraZeneca employees worked 
tirelessly to ensure the safety of patients 
and their continued access to care and 
medicines. We also worked with partners 
across the world to contribute to the 
processofscientificinnovationtocombat
the virus and contributed more broadly to 
society, including with emergency relief. 
At the same time, the ground-breaking 
scientificadvanceswedeliveredin2020
demonstrate what can be achieved in the 
mostdifficulttimesifweliveourValues
and are true to our Purpose.
In addition to the pandemic, racial equity 
and environmental crises taught us that our 
society is fragile. The world has to come 
together to overcome these challenges 
if we are to build a sustainable world for 
future generations.
At AstraZeneca, our focus on 
sustainability is fundamental to our 
strategy and, despite the challenges, 
our teams continued to make great 
progress in 2020 across our three 
sustainability pillars — increasing access 
to healthcare, protecting the environment, 
and demonstrating our commitment to 
ethicsandtransparency.Alloureffortsare
underpinned by our commitment to the 
United Nations Sustainable Development 
Goals and the United Nations Global 
Compact’s 10 principles on human rights.
Our Access to healthcare activities in 
2020 included a focus on programmes to 
strengthen health system resilience at a 
time when the need for disease prevention 
and treatment has never been more 
important. And, with the bold commitments 
we have made through our Ambition Zero 
Carbon strategy, we are actively playing our 
part in tackling the climate emergency. 
2021 provides an opportunity 
for us to build a more sustainable 
future as the world emerges from the 
pandemic. Every change — large or 
small—canmakeadifference.
—  Pascal Soriot, AstraZeneca CEO
"I am proud of the fact that, 
in the face of the pandemic, 
AstraZeneca employees 
worked tirelessly to ensure the 
safety of patients and their 
continued access to 
care and medicines." 
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Sustainability
at AstraZeneca
Using our capabilities to 
make the most meaningful 
impact where society 





























AstraZeneca is about using 
our capabilities to make 
the most meaningful impact 
where society needs it — 
health. We know the health 
of people, the planet and our 
business are interconnected, 
each impacting the others.
Our goal is to always be moving 
our organisation towards greater 
sustainability. Our efforts in sustainability 
go beyond meeting our annual and 
longer-term targets. We must continually 
evolve our mindset and our practices 
to meet changing times. This is both a 
responsibility and a business opportunity.
Our sustainability strategy 
Our sustainability strategy is guided by a 
materiality assessment. This robust process 
determines the topics that are most important to 
AstraZeneca and our stakeholders, giving us the 
opportunity to achieve the most positive impact. 
We have 16 material focus areas, which are 
grouped under three interconnected priorities — 
Access to healthcare, Environmental protection 
and Ethics and transparency
Our ambitions 
 Work towards a future where all people have 
access to sustainable healthcare solutions for 
life-changing treatment and prevention
 Demonstrate global leadership to proactively 
manage our environmental impact across 
all our activities and products
Create positive societal impact and promote 
ethical behaviour in all markets across our 
value chain
Our sustainability approach 
Systems thinking — recognising that 
our globalised world binds us together 
in a dynamic, complex network of 
relationships. We know the health of 
people (including our workforce, patients 
and society at large), the planet and 
our business are interconnected. The 
scale and severity of the issues we face 
today require us to assess all options 
simultaneously. We look for opportunities 
thatoffersynergiesandaddress
systemic issues





Aiming to leave things better than we 
found them—wedifferentiatebetween
addressing our negative environmental 
impacts and creating the conditions for 
deep, lasting sustainability
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Business operating model
Sustainability is a core element of our company strategy. Being a Great Place to Work is 
one of our three corporate strategic priorities. Our performance is assessed by the delivery of 
short- and long-term sustainability targets for our 16 material focus areas. These targets are a 
part of the company’s global internal scorecard, against which we measure our progress as a 
business, and every employee contributes to their achievement.  
    See Sustainability Data Summary for full metrics and methodology.
Workforce engagement 
Our leaders and employees participate in events and initiatives throughout the year— from 
the annual Senior Leaders' Meeting to digital crowdsourcing — to raise awareness of our 
sustainability strategy and further embed a sustainability mindset across the business, 
generating new approaches and challenging ourselves to do better. In our latest employee 
survey, 87% of respondents stated they understand how to contribute to our sustainability 
priorities. See more in Stakeholder engagement.
Investor relations
We incorporate sustainability-related disclosures into public announcements for 
analysts, institutional investors and rating agencies. We have a dedicated Environmental, 
SocialandGovernance(ESG)investorrelationsofficerand,throughout2020,our
Investor Relations (IR) team has engaged in more than 70 external events with more 
than 300 stakeholders. See more in Stakeholder engagement. 
Risk management
We recognise the connection between enterprise risk management and sustainability 
management. In 2018, enterprise risk management informed the 
sustainability materiality assessment and we used the results to better align our risk 
andsustainabilityclassifications.TheGlobalSustainabilityfunctionparticipatesin
quarterly company risk reviews. In 2020, climate related material focus areas were 
explicitly incorporated in the risk management platform to enable risk managers to 
flagwhenpotentialrisksareconnectedtoenvironmentalsustainabilityissues. 
See more in the Risk overview section of our Annual Report. 
Code of Ethics
Our Code of Ethics is based on our company Values. It provides clear guidance and 
direction to employees in carrying out their daily work. Sustainability is featured as one 
of four high-level global policies in the Code of Ethics. Annual training on the Code is 
mandatory for all employees. See more in Ethical business culture.
Sustainability business integration
Sustainability is an imperative. 
It's the right thing to do — 
for people, the planet and our 
business. Sustainability is 
an engine for innovation.
Integrating sustainability 
into everything that we do 
future-proofs our business to 
be resilient in challenging times, 
helping ensure we can continue 
to deliver life-changing medicines 
to patients. With this in mind, we 
seek to integrate sustainability 
into every aspect of our enterprise. 
We have the following practices 




Using our capabilities to 
make the most meaningful 
impact where society 
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2020 performance highlights
89%
of employee survey 
respondents feel that 
AstraZeneca is a 
Great Place to Work
49.1
instances of non-compliance 
with the Code of Ethics 




new supplier diversity 
programmes
132,000+
healthcare workers trained1 
(cumulative)
10m+
people reached though our 
Patient Assistance Programmes (cumulative)
84%
of employee survey 
respondents feel that 
AstraZeneca has a 
‘Speak Up’ culture
9 
members govern sustainability on our 
Sustainability Advisory Board — composed of four external 
experts and five Senior Executive Team (SET) members
1 of 3
Sustainability is a component of 
Great Place to Work, one of our 
three company strategic priorities 
30+
performance metrics 
measured quarterly in the 
internal company scorecard 
100%
of active pharmaceutical ingredient discharges (API) from 
AstraZeneca owned sites demonstrated as safe; 94% of 
discharges from direct suppliers demonstrated as safe2
60%
reduction in Scope 1 and 2 








our water use 
since 2015
25m+ 
people reached through our 
access programmes1 (cumulative) 
46.9%
women in senior 
middle management 
roles and above
We recognise that several of these measures were impacted 
by the pandemic and may not reflect a typical trajectory.
    See Sustainability Data Summary for full metrics and methodology.
Access to healthcare
Work towards a future where 
all people have access to 
sustainable healthcare solutions 
for life-changing treatment 
and prevention
Environmental protection
Demonstrate global leadership 




Create positive societal impact 
and promote ethical behaviour 
in all markets across our 
value chain
Sustainability strategy
Use our capabilities to make 
the most meaningful impact 
where society needs it — health
1st
life cycle assessment 
study completed for 
a clinical trial
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Strategic R&D centres:
Cambridge,UK(HQ);Gaithersburg,MD,US;Gothenburg,Sweden
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Deliver Growth and 
Therapy Area Leadership 
Accelerate 
Innovative Science 

































We push the boundaries of science 
to deliver life-changing medicines. 
We are a global, science-led, patient-focused 
pharmaceutical company. We discover, develop 
and commercialise prescription medicines. We 
follow the science to transform how diseases are 
understood, interact and impact one another. 
Our medicines primarily treat diseases in three 
therapy areas:
Oncology
Our ambition is to provide cures for cancer in 
every form. We are following the science to 
understand cancer and all its complexities to 
discover, develop and deliver life-changing 
treatments and increase the potential for cure.
Cardiovascular, renal and 
metabolism (CVRM)
Our mission is to protect the lives of people 
from the consequences of CVRM diseases. 
We are committed to their seamless management, 
improving patient outcomes and decreasing 
the mortality rate.
Respiratory and immunology (R&I)
We aim to transform the treatment of R&I diseases, 
with the bold ambition to eliminate preventable 
attacks and achieve durable remission or even 
cure for millions of people with these potentially 
devastating conditions.
About us
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COVID-19 pandemic actions
AstraZeneca’s response 
to the COVID-19 pandemic 
was consistent with our 
Values of following the 
science, putting patients 
first and doing the right 
thing. Our priorities 
were driven by the needs 
of patients, caregivers 
and communities.
Torespondeffectively,wepartnered
with governments, international 
organisations, health professionals, 
industryandnon-profitorganisations.
Ourresponsealsoreflected
our sustainability priorities. 
Access to healthcare
Our objectives and actions:
Help ensure continued access to care 
and medicines
•  Redesigned clinical trials to avoid 
disruption by increasing the use of 
initiatives like home-based treatments 
and remote monitoring
• Pledgedfinancialcommitmentstodozens
of patient advocacy groups and professional 
societies across the globe to prioritise continuity 
of care during the pandemic
•  Lead donor of the COVID Impacts Cancer Initiative 
— launched by the American Society of Clinical 
Oncology — to establish a registry for its members 
to share data on how the coronavirus impacts care 
and patient outcomes
•  Launched our Partnership for Health System 
Sustainability and Resilience, with the World 
Economic Forum and the London School of 
Economics, to identify solutions to strengthen 
the resilience of healthcare systems
 Protect critical operations to ensure the 
continued supply of our medicines to patients 
who need them
• Monitored more than 1,300 global logistics 
routestoensuretheefficientflowofmedicines,
enabling us to continue to deliver our medicines 
and respond to the growth in global demand for 
some medicines
Ethics and transparency
Our objectives and actions:
Ensure the safety and wellbeing of our employees
• Launched a secure digital platform for more than 77,000 employees and contract workers in 
eightdayssothatmostemployees,includingsomelaboratorystaff,couldworkfromhome
• In locations where employees remained in or were able to return to their place of work, additional 
health and safety measures were put in place, including temperature screenings, physical 
distancing and mandatory mask-wearing
• Administered more than 50,000 PCR and antibody assessments for employees at key sites
• ProvidedsupportandguidancetoemployeeswithsuspectedorconfirmedCOVID-19
• Launched toolkits for employees and leadersincludingadviceonworkingeffectivelyfromhome
while maintaining physical and mental wellbeing. We shared these toolkits externally for other 
organisations to use and repurpose
• Assistedemployeeswhoworkedonsitetofindavailableplacesatnurseriesandwith
registered childminders
Contribute more broadly to society
• Updated our Global Volunteering Policy, extending the amount of leave for medically trained 
employees, and encouraged volunteering more generally to relieve exhausted health systems 
and support communities 
• Provided more than $15 million in COVID-19 donations to patient advocacy groups, 
healthcharitiesandreliefagencies,supporting340non-profitorganisationsin78countries
Environmental protection 
Our objectives and actions:
Remain steadfast in our commitment to environmental protection 
• Conducted environmental risk assessments in line with local 
regulatory requirements during research and development of potential 
COVID-19 treatments 
• Co-authored a 10-point action plan to create a circular bioeconomy, 
recognising deforestation, biodiversity loss and landscape fragmentation 
askeyprocessesenablingtransmissionofzoonoticinfectiousdiseases
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Contribution to the SDGs
What are the SDGs?
The United Nations Sustainable 
Development Goals (SDGs) are 
a universal blueprint for prosperity 
for people and the planet, now 
and into the future. They represent 
the collective actions the world 
can take to address the most 
pressing issues we face as a global 
community — inequality, injustice, 
poverty and climate change.
Why they matter
SDG 3 
Good health and wellbeing
COVID-19 has shown the vulnerability of many 
global systems in a crisis setting, resulting in the 
loss of human life and widespread economic 
downturn. Both communicable pandemics2 and 
non-communicable diseases (NCDs)3 are projected 
to increase, and health systems will need to 
become more resilient to continue to provide 
services to those in need. Furthermore, NCDs kill 
more than 41 million people each year, which is 
equivalent to 71% of all deaths globally.4
SDG 5 
Gender equality
Supporting women is essential to promote 
health and enhance business performance. 
Women’s equality in the workplace could add 
as much as $28 trillion to global annual gross 
domestic product by 2025.5 If business as usual 
is maintained, it would take 202 years to achieve 
gender equality in the workplace.6
SDG 8 
Decent work and economic growth
Inequality is rising globally and there are not 
enough jobs to keep up with a growing labour 
force.AlthoughCOVID-19offersopportunities
to improve work-life balance through reduced 
business travel and remote working, it has also 
accelerated and exacerbated existing work 
inequalities, especially for the most vulnerable. 
Certain groups — such as workers with disabilities, 
women and migrants, among others — face 
significantobstaclesinaccessingdecentworkand




Economic and social progress over the last 
century has been accompanied by environmental 
degradation that is endangering the systems upon 
which our future development and survival depend. 
Production and consumption patterns need to 





existence, from access to water and food, to 
severe weather events and pollution, resulting in 
health issues. Even with widespread restrictions 
upon travel and huge shifts in energy demand 
around the world, emissions reductions in 
2020 were not enough to keep warming to 
1.5°C in the future.9
SDG 17 
Partnership for the goals 
Nooneindustryoractoraloneissufficient
to address the converging health and climate 
crises. A multitude of actions, initiatives and 
investments are necessary. The more coordinated, 
andmutuallyreinforcingtheseeffortsare,the
higher the likelihood of setting society on a 
transformative path towards a more resilient future. 
The 17 SDGs are interconnected. Contribution to 
oneSDGwillaffectoutcomesinothers,therefore
sustainability initiatives must balance social, 
economic and environmental aspects.
These Global Goals recognise the synergies 
between improving economic prosperity, health, 
education and the environment, to set society 
on a transformative path towards a more resilient 
and sustainable future. 
Our prioritisation process
While we recognise that our business impacts 
all 17 SDGs to varying degrees, we evaluate 
our primary contribution1 by:
• Connecting our long-term targets and annual 
progress to SDG targets
• Analysing the 169 SDG underlying targets 
and connecting them to our material focus areas 
and future strategic direction 
The six goals and 12 targets that resulted from this 
prioritisation represent where AstraZeneca has the 
greatest capacity for impact and action. 
    See Sustainability Data Summary 
for more detailed information.
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Our primary SDG contributions
3.4 Reduce premature mortality from NCDs
Over 25 million people reached through 
Access to healthcare programmes,10 
since 2010. 2025 target is 50 million. 
3.6 Halve the number of global deaths and 
injuries from road traffic accidents
46% reduction in the vehicle collision rate of our 
workforce since 2015. 2025 target is 55%. 
3.8 Achieve universal health coverage
Over 3,340 health facilities activated or 
partnered since 2015.
3.c Increase the health workforce in 
developing countries
Over 132,000 healthcare workers trained10 
since 2010. 2025 target is 170,000.
    See Sustainability Data Summary for full metrics and methodology.
SDG 3 | Good health and wellbeing
5.5 Ensure women’s full and effective participation and equal opportunities for 
leadership at all levels of decision-making in political, economic and public life
46.9% of senior middle management roles and above held by women, up from 
45.4% in 2019. 2025 target is 50%. 
50.5% of all AstraZeneca employees are women, up from 50% in 2019.
35.7% women representation on Board of Directors, up from 33.3% in 2019.
SDG 5 | Gender equality
8.8 Protect labour rights and promote safe and secure 
working environments for all workers
64% reduction in reportable injury rate from 2015 baseline. 
2025 target is 75%. 
SDG 8 | Decent work and economic growth
17.17 Encourage and promote effective public, 
public–private and civil society partnerships
Patron sponsor for the United Nations' Goal 3 action platform, 
Healthy People Healthy Planet.
Committed to the United Nations Women's Empowerment Principles.
Signatories of the United Nations Global Compact (UNGC) since 
2010 and joined as Participants in 2018.
UNGC's Our Only Future member.
SDG 17 | Partnership for the goals11
13.1 Strengthen resilience and adaptive capacity to climate-
related hazards and natural disasters in all countries
60% reduction in Scope 1 and 2 
emissions from 2015 baseline. 
2025 target is 100%.
3% increase in Scope 3 
emissions from 2015 baseline. 
2030 target is to be carbon 
negative.
SDG 13 | Climate action
12.2 Achieve the sustainable management 
and efficient use of natural resources
20% reduction in water use since 2015. 
2025 target is to maintain absolute water use 
at 2015 baseline levels.
67% of active pharmaceutical ingredient (API) 
synthesesmetresourceefficiencytargetssince
2015, up from 50% in 2019. 2025 target is 90%.
12.4 Achieve the environmentally sound 
management of chemicals and all wastes, 
and reduce their release to air, water and soil
100% of API discharges from AstraZeneca sites 
assessed as safe and 94% from suppliers.12
12.5 Reduce waste generation through 
prevention, reduction, recycling and reuse
2% reduction in our waste since 2015. 
2025 target is 10% below 2015 baseline.
40% of total waste is recycled, down from 
44% in 2019. 
12.6 Encourage companies to adopt 
sustainable practices and to integrate 
sustainability information into their 
reporting cycle
61.3% of critical manufacturing suppliers 
disclosed their energy, waste and water 
footprint, up from 60.7% in 2019. 
SDG 12 | Responsible consumption and production
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EVP, Sustainability and 
Chief Compliance Officer, 
President AstraZeneca AB, 
Sweden.  
Daria Buhaichuk, Sustainability Data 
Analysis and Visualisation, Warsaw, 
Poland, speaks with Katarina Ageborg 
about sustainability in 2020.
DB: How have the events of 2020 impacted 
AstraZeneca’s sustainability agenda?
KA: The spotlight on global crises like the 
COVID-19 pandemic, mass-protests against 
racial inequality and ongoing concerns about the 
accelerating rate of climate change have only 
increased our focus on sustainability over the past 
year. These issues are interconnected, with health 
inequities meaning the impacts of the pandemic 
and climate change will be felt hardest by those 
most in need. We must continue to work together 
across sectors and with governments to support 
a sustainable recovery and address the connection 
between the health of the planet and the health 
of people.
DB: What sustainability progress 
from AstraZeneca were you most 
excited about? 
KA: Our Ambition Zero Carbon strategy to make 
AstraZeneca’s global operations responsible for 
zerocarbonemissionsby2025,withoutrelyingon
offsetschemes,andtobecarbonnegativeacross
our entire value chain by 2030, puts us amongst the 
climate action leaders across all industries — this 
makes me very proud to be part of this company. 
There is of course a lot of work to do to achieve 
ourboldcommitments;wemustcollaborate
and partner with governments, non-government 
organisations (NGOs) and other public and private 
sector organisations, as well as our industry peers, 
to drive the investment, policy and infrastructure 
changes to make it happen. We hope that by 
working in partnership, as we have seen on vaccine 
development, and driving industry action, we can 
move towards a more sustainable approach for 
the healthcare sector overall.
DB: How are teams in AstraZeneca 
responding to this challenge?   
KA: Ouremployeeshaveamazingpassion
and enthusiasm for our sustainability work and 
make sure that we step up to make a valuable 
contribution to society. Colleagues across the 
company used crowdsourcing to innovate around 
how we will achieve our climate targets. By the end 
of 2020, we were sourcing almost 100% renewable 
electricity across our sites worldwide. Our teams 
are working hard to determine the steps we need to 
take over this decade of delivery to get us to carbon 
negativeacrossourvaluechainby2030;they
understand that there is a vital connection between 
the health of the planet and people’s health, as well 
as the future success of our company.
DB: What have been the positives you have 
taken away from a tough 2020? 
KA: There have been many positive takeaways 
from 2020, including playing our part to eliminate 
discrimination from the delivery of healthcare, 
looking to ensure our workforce is representative 
of the communities in which we operate, taking 
action to increase minority representation across 
our talent pipeline and rolling out anti-discrimination 
training.Ourfirst-everPowerofDiversityWeekwas
a global, virtual, tough conversation on what more 
we can do and how to do it. We also celebrated 
diversity and reminded ourselves of the value of 
an inclusive culture. These steps underline our 
commitment to driving societal change within 
and beyond AstraZeneca.
Another highlight is the rapid acceleration of digital 
and virtual working, which has enabled us to 
effectivelycontinueservingpatientsandsociety
when away from AstraZeneca sites, which has also 
reduced our business air travel by 86%. Together 
with extra wellbeing and mental health support for 
employees, I am extremely proud of how we have 
pulled together, lived our Values, and made our 




have amazing passion 
and enthusiasm for our 
sustainability work and make 
sure that we step up to make 
a valuable contribution 
to society."
Daria Buhaichuk
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Sustainability governance 
continued
The board reviews the 
sustainability scorecard each 
quarter. In 2020, the board 
deliberated on sustainability 
matters XX times. Sum 
laccumquae vid te ulluptios 
ipsaperibus sequaer chiligent 
quis vellab. 
AstraZeneca Board and SET members
Pascal Soriot 
CEO and Executive Director of the Board  
Joined the World Economic Forum's Sustainable 
Markets Council, an advisory body of public-private-
philanthropic leaders to drive sustainable solutions in line 
with the United Nation’s Sustainable Development Goals. 
He is also Chair of the AstraZeneca Global Inclusion and 
Diversity Council, and a member of our Ambition Zero 
Carbon Governance Group that is accountable for key 
investment decisions for our climate strategy.
Marc Dunoyer 
CFO and Executive Director of the Board  
Executive Sponsor of our philanthropic 
Young Health Programme which works to help young 
people take control of their health and prevent 
non-communicable diseases in 24 countries. 
He is also a member of our Ambition Zero Carbon 
Governance Group.
AstraZeneca SET and SAB members
• EVP,SustainabilityandChiefComplianceOfficer
• EVP, Operations and IT
• EVP, BioPharmaceuticals R&D
• EVP, International
• EVP, Human Resources




sustainability strategy execution, including tracking our progress towards targets and working together 
with company leadership to ensure strategy is aligned with business priorities.
Our Sustainability Advisory Board comprises SET members and external sustainability experts. 
It met in 2020 to approve strategic direction, recommend opportunities and provide insight. 
Key discussions included:
• Ambition Zero Carbon plans
• Product Sustainability Index
• Impacts of systemic racism on access to healthcare
Value from external advisers
Each adviser has deep expertise in one or 
moresustainabilityfields,spanningclimate
change, access to healthcare, operations, 
strategy integration, human rights and product 
environmental stewardship.
This range of perspectives helps us to understand 
the diverse concerns of external stakeholder 
groups.Theadvisersofferinsightsfromother
sectors and industries that we may not have 
considered otherwise. Most importantly, they 




Deputy Director, Climate Program and Global 
Director, GHG Protocol, World Resources Institute
Dame Polly Courtice, DBE, LVO 
Director, Cambridge Institute for Sustainability 
Leadership, University of Cambridge
 Rain Henderson 
Founder, Elementor Advisors
Louise Nicholls 









The AstraZeneca Board of Directors reviews our internal sustainability scorecard each quarter. In 2020, 
the Board deliberated on sustainability matters including about the physical and transitional risks and 
opportunities posed to AstraZeneca by climate change, as guided by the Taskforce on Climate-related 
Financial Disclosures (TCFD) framework. See the AstraZeneca TCFD disclosure statement within our 
Annual Report. 
Geneviève Berger 
Non-Executive Director of the AstraZeneca Board 




Chairman of the Board  
Represents AstraZeneca on the Reform for resilience — The Post-Pandemic Policy Commission, leading 
the healthcare resilience and sustainability pillar. This new global initiative provides policy recommendations 
for G7 and G20 political leaders. We are the only healthcare company on this Commission.
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Stakeholder engagement
We value the diverse 
perspectives of stakeholders inside 
and outside our business. They 
help us shape and implement 
our sustainability strategy. 
We recognise the importance of not only those 
environmental, social and governance (ESG) 
issues that impact our business, but also how our 
business impacts ESG matters. We gather broad 
stakeholderinputtohelpusrefineourapproach.
It is through open and transparent dialogue with our 
stakeholders that we uncover solutions to advance 
the health of people, the planet and our business.  
We use a wide range of communication 
channels with our stakeholders, including digital 
engagements, face-to-face dialogue and group 
settings. Our Code of Ethics guides our approach. 
You can read more about how stakeholders can 
raise concerns in Ethical business culture. 
Engaging to shape our priorities —
Materiality assessment
AstraZeneca’s sustainability strategy is guided by 
amaterialityassessment.Thisassessmentidentifies
the ESG issues that matter most to AstraZeneca 
and our stakeholders, and that represent where 
we have greatest capacity for impact and action. 
We continually assess our strategy by examining 
emergingtopics,significanttrendsandengaging
internal and external stakeholders. 
Our most recent sustainability materiality 
assessment was conducted in 2018. In 
collaboration with an independent consultancy, this 
assessmentidentified16material focus areas that 
maximise our opportunity for impact. This narrowed 
our priorities by about half. Our process was 
rigorous and comprehensive, given its geographic 
breadth, depth of input from stakeholders and 
alignment with enterprise risks.
Low High






























We actively seek 
stakeholders’ input to 
help us refine our approach. 
It is through open and 
transparent dialogue with our 
stakeholders that we uncover 
solutions to advance the 
health of people, the planet 
and our business.  
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We are continually evolving our ways of working to 
address the current and future needs of patients. 
We engage with patients in many ways: through 
patient advocacy groups, advisory boards and 
patientpanelsonspecifictherapyareas;market
research;andthroughtechnologytoconnectwith
patient communities so they don’t need to travel. 
In 2020, we launched our internal global patient 
centricity scorecard to keep us accountable for 
moving towards a more holistic, patient-centric 
business model. We set goals for 2025 across 





HCPs are essential partners, providing insights that 
help us improve how we develop and deliver our 
medicinesformaximumpatientbenefit.Weengage
HCPs through advisory boards, clinical trials 
and educational events including independent 
events and congresses. In 2020, we provided and 
supported early platforms for physicians to share 
their experience of treating patients with COVID-19. 
We also responded to more than 118,000 HCP 
enquiries and processed over 21,000 adverse 
event reports from HCPs. 
Communities
We aim to make a positive impact on the 
communities in which we operate, as well as those 
which our medicines reach. In 2020, we provided 
more than $76 million in community investment 
sponsorships, partnerships, charitable and product 
donations worldwide. We also donated more than 
$1.6 billion of medicines in connection with  
Patient Assistance Programmes (PAP), the largest 
of which is our AZ&Me programme in the US.
Suppliers
We work with suppliers that support us to deliver 
our sustainability agenda. We engage directly 
through virtual and in-person meetings to build 
suppliers' sustainability awareness and capabilities. 
All of our critical manufacturing partners participate 
in the Sustainability Partner Guide and Framework, 
which includes sustainability assessments such as 
EcoVadis and EcoDesk. To maximise our impact, 
we participate in cross-industry forums such as 
the Pharmaceutical Supply Chain Initiative (PSCI). 
In 2020, we continued work with suppliers to 
improve the measurement of our value chain's 
greenhouse gas (GHG)  emissions footprint. 
This supports our Ambition Zero Carbon targets. 
See more in Responsible supply chain.
Workforce
In our employee survey, 87% of respondents stated 
they understand how to contribute to AstraZeneca’s 
sustainability priorities. 
We hold local and global events to engage our 
workforce in collectively achieving our sustainability 
goals. Dialogue and collaboration is facilitated 
through our internal social media platform, which 
was used in 2020 for a series of events. The 
COVID-19: Now and Next crowdsourcing campaign 
focused on ideas around what we had learned from 
the pandemic and how to accelerate the delivery of 
our company strategy and increase our resilience 
to future shocks. The Ambition Zero Carbon: 
Decade to Deliver campaign generated ideas from 
employees to help us reach our GHG emissions 
2030 target to be carbon negative in our value 
chain.Ourfirst-everglobalPower of Diversity Week 
included activities to raise awareness around 
the role every employee plays in progressing our 
inclusion and diversity priorities.  
Analysts, institutional investors 
and rating agencies
Weactivelyengagewithfinancialstakeholders
on sustainability-related topics via one-to-one 
meetings, conferences, management roadshows 
and other events, tracking engagement topics via 
our customer relationship management system. 
We share periodic sustainability-related updates 
with analysts, institutional investors, rating 
agencies — including credit and sustainability 
— through direct outreach and in a dedicated 
section within our full-year and quarterly 
results announcements and presentations. 
In2020,wehostedAstraZeneca’sfirst-ever
ESG event: Meet AZN management: Leading in 
sustainability, led by Non-Executive Chairman 
of the Board, Leif Johansson. More than 240 
unique participants attended the event and rated it 
4 out of 5, for both the overall quality of the event 
and the ability of AstraZeneca to communicate 
its sustainability strategy. AstraZeneca was 
voted second for ‘Best overall ESG’ in the 2020 
Institutional Investor survey, highlighting our 
continued progress in integrating sustainability 
into our business. 
Government bodies and regulators
We hold regular meetings, roundtables and 
events to increase understanding about how 
governments can improve patient access to new 
medicines. In 2020, most of our work focused on 
collaboratingwithgovernmentstofindsolutionsto
end the COVID-19 pandemic. We also engaged in 
discussions on evolving the current reimbursement 
system for medicines in the US.
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Connection to health:
Innovative healthcare solutions 

































Health is key for people, planet 
and business to thrive
Our ambition:
Work towards a future 
where all people have 
access to sustainable 
healthcare solutions for 
life-changing treatment 
and prevention
Contributing to the 
Sustainable Development Goals, 
a universal blueprint for prosperity 
for people and the planet, now and 
into the future.
SDG 3 | Good health and wellbeing
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Access to healthcare at 
AstraZeneca goes beyond our 
medicines. We provide healthcare 
solutions along a continuum 
of care — from prevention, 
awareness, diagnosis and 
treatment, to post-treatment 
and wellness. We work across 
our main therapy areas to 
address unmet medical needs 
and health disparities.  
The big picture
We recognise health as a human right. Healthcare 
isourcorebusiness;ourmissionistopushthe
boundaries of science to deliver life-changing 
medicines. The COVID-19 pandemic has 
demonstrated that health is foundational to a 
well-functioning society and economy. The 
pandemic has also tested the resilience of 
healthcare systems. AstraZeneca is committed 
to increase resilience to future shocks, so that 
people, the planet and our business can thrive 
well into the future. 
Access to healthcare approach
We are working towards a future where all people 
have access to sustainable healthcare solutions for 
life-changing treatment and prevention.
How do we do this? 
Innovating — to deliver life-changing medicine
Partnering—toimproveaccessandaffordability
Transforming — for the future of healthcare
2020 updates
Innovating: We seek to future-proof global health 
systems to ensure that our medicines get to people 
who need them, even when challenges exist 
within those healthcare systems. We launched the 
Partnership for Health System Sustainability and 
Resilience (PHSSR) with the London School 
of Economics (LSE) and the World Economic 
Forum (WEF).
Partnering: We are patient centric and recognise 
thatpatientsarepeoplefirst.Weareevolvingour
ways of working to address the current and future 
needs of patients. We work with partners to help 
create integrated healthcare ecosystems that bring 
benefitsandsupportforthewholeofthepatient
experience. We also co-chair the Private Sector 
Roundtable (PSRT) on Global Health Security, which 
mobilises industry to help countries prevent, detect 
and respond to health security-related threats. 
We know we can achieve better health outcomes 
for all in partnership with other organisations. 
Transforming: We commit to health equity — 
to ensuring that everyone has an equal opportunity 
to be as healthy as possible. We are working 
to address health disparities and eliminate 
discrimination from the delivery of healthcare. This 
includes ensuring equity in our workplace, access 
to our medicines, in our clinical trials and beyond. 
Our internal initiatives place a strong emphasis on 
the role of health in workforce wellbeing and safety, 
our supply chain and environmental stewardship.
Governance
The scope of our Access to healthcare material 
focus areas applies across our business operations, 
so we work to collaborate across functions to 
deliver our strategy and outcomes. We support our 
global workforce to make their unique contributions 
to our Access to healthcare goals. An Access 
to healthcare working group convenes regularly. 
OurunifiedquarterlyscorecardtracksAccess
to healthcare metrics and communicates our 
performance to all employees.
Access to healthcare overview
  Material focus areas
Ourstrategyaddressesfivefocusareas, 
asidentifiedbyourmateriality assessment:
Disease prevention and treatment
Responsible research and development
Environment’s impact on health




• Disease prevention and treatment:  
Launched the Take CaRe of Me programme 
to promote early awareness of type 2 
diabetes complications
• Responsible research and development: 
Committed to diversity in clinical trials
• Environment’s impact on health: 
Initiated air pollution research in Uganda in 
partnership with the Cambridge Institute for 
Sustainability Leadership
• Investments in health systems: Launched 
partnership for Health System Sustainability 
and Resilience with LSE and WEF
• Affordability: Entered into over 
100 value-based agreements
• Overall: Ranked 7th out of 20 companies in 
the Access to Medicines Index (ATMI)AstraZeneca colleague presents at 
Healthy Heart Africa 
expansion into Uganda.
We recognise that several of our annual 
Access to healthcare measures were 
impacted by the pandemic and may not 
reflect a typical trajectory.
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The journey towards 
health system resilience 































Improve preparedness for future 
shocks and enhance international 
coordination on key processes 
such as scenario planning, response 
protocols and reserve capacities
Optimise the location and 
focus of care on patients using 
digital technologies
Address the unsustainable 
social, economic and ecological 
costs of disease through more 
aggressive prevention
Improve the effectiveness of 
care for chronic diseases through 




















Even before COVID-19, many health systems 
hadsignificantlimitationsinreachingthose
with unmet medical needs. The pandemic has 
revealed and exacerbated such pre-existing 
weaknesses in health systems, and has 
demonstrated the urgent need to build more 
resilient health systems worldwide.
The need:
Build health systems 
to be stronger and 
more resilient 
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Young Health Programme (YHP) in Kenya.
Why it matters
We are committed to health equity 
— to ensuring that everyone has 
an equal opportunity to be as 
healthy as possible by removing 
barriers to access and eliminating 
discrimination from the delivery 
of healthcare.
We recognise that non-communicable diseases 
(NCDs), such as cancer, diabetes, heart disease 
and respiratory conditions: 
• Should be addressed from an intersectional lens, 
as they disproportionately impact marginalised 
groups: communities of colour, low- and middle-
income populations1 and women,2 among others 
• Are responsible for 71% of deaths globally3 and 
are the number one cause of death and disability, 
placingasignificantburdenonhealthsystems4
• Are estimated to cost the global economy 
$47 trillion by 2030 in lost productivity5 
We have the responsibility and opportunity to 
leverageandscaleourscientificexpertiseto
develop healthcare solutions that address existing 
health inequities. Additionally, we remain responsive 
to global health imperatives, such as the COVID-19 
pandemic. In 2020, we invested resources into 
prevention activities from equipment donations, 
to access programme resource reallocation, 
to vaccine and treatment development. 
 Description
Company activities aimed at preventing the onset 
and progression of diseases (including NCDs).
 Approach
With healthcare as our core business, we seek 
to prevent disease and support people on their 
path to better health. We do this through health 
promotion, advocacy and research. For those who 
have been diagnosed with a condition, we strive 
toensureaccesstoeffectivetreatment.
Our work focuses on:
Concentrating our portfolio on our 
threemaintherapyareas:oncology;
cardiovascular, renal and metabolic 
diseases;andrespiratorydiseases
Being patient centric — our 
longstanding commitment to 
patients has led us to reimagine our 
patient-focused ways of working. 
We embed it across every aspect of 
our company to deliver the healthcare 
experience and outcomes people 
care about most so they can enjoy 
fulfillinglives
Breaking down cultural 
barriers to improve treatment 
adherence
Collaborating with experts at 
leading organisations to better 
understand diseases and accelerate 
drug development 
Disease prevention and treatment
2025 target
Maintain the Young 
Health Programme 
(YHP) in current active 
markets and expand 




YHP added six new 
markets, reaching a total of 
24 markets. We launched 
new programmes in 
two countries and 
accelerator programmes 
in six countries.
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to these 
Sustainable Development Goals:
SDG 3 | Good health and wellbeing 
SDG 17 | Partnership for the goals
 Key target and progress
Disease prevention and treatment 
is closely related to other areas of 
our sustainability strategy.
Investments in health systems 
and Workforce wellbeing and safety 
both feature prevention initiatives. 
In 2020, our 
YHP started a 
new partnership with 
UNICEF to shape 
12 policies and 
laws and train 
1,000 youth 
advocates.
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Take CaRe of Me programme 
Many non-communicable diseases (NCDs) are 
interrelated;developingoneNCDcanincrease
the risk of developing other NCDs. For example, 
patients with type 2 diabetes (T2D) have a greater 
risk of developing cardiovascular disease and 
chronic kidney disease, a risk that further increases 
if the disease is not diagnosed and treated early.6 
Studies estimate that up to 36% of T2D patients 
will develop chronic kidney disease and 24% will 
develop heart failure.7 Such interconnectivity is 
well established, yet awareness in developing 
nations remains limited, providing a barrier to 
effective,potentiallylife-savingtreatment.This
situation highlights the importance of addressing 
T2D holistically, as opposed to addressing 
health issues separately.
In 2020, we recognised World Diabetes Day by 
launching the Take CaRe of Me programme (C for 
cardiovascular, R for renal and M for metabolic) 
— a holistic patient care and evidence generation 
initiative that promotes the early awareness of T2D 
complications. The main goal is to improve patient 
outcomes by driving early recognition, diagnosis, 
referral and management of long-term risks, having 
a direct impact in patient outcomes through: 
Integrating advanced diagnostic technologies 
into patient pathways to support primary care 
physicianstomoreeffectivelyprofileand
identify patients who are at risk of associated 
cardio-renal complications
Utilisingartificialintelligenceanalyticsand
advanced point-of-care diagnostic devices 
to generate data that highlights the increased 
susceptibility of patients, enabling primary care 
physiciansintheearlyidentification,prevention,
and potential treatment of these comorbidities
Raising patients' awareness of early 
complications of T2D
We have partnered with Tricog Health to deliver 
our goals. The programme is active in six countries 
— Egypt, Mexico, the Philippines, India, Malaysia 
and Argentina. Take CaRe of Me currently has the 
potential to impact the lives of around 155 million 
patients with T2D.
Health Innovation Hubs — 
Increasing access to healthcare 
As technology becomes integrated into the delivery 
of healthcare, medicines can no longer be viewed 
in isolation from other aspects of a patient’s 
care. We are co-creating solutions with and for 
patients, and working with partners to establish 
integratedhealthcareecosystemsthatbenefitthe
whole patient experience — from prevention and 
awareness, diagnosis and treatment to 
post-treatment and wellness. 
Our Health Innovation Hubs are a network of 
physical locations and virtual partnerships to solve 
challenges, and scale and showcase healthcare 
solutions. We have 10 major iHubs and more 
than 20 local ecosystem solutions that form an 
interconnected global network to deliver integrated 
care and holistic disease management across all 
our therapy areas. Our Hubs put us at the centre of 
interaction between patients, medicine, technology, 
healthcare professionals and policy makers to 
reimagine how we can improve patient outcomes. 
We do this by: 
• Establishing public-private partnerships based 
on a shared innovation agenda
• Co-creating with the entire patient network 
(caregivers, family, friends, co-workers, 
healthcare professionals and others) 
to help inform start-up companies and 
technology partners
• Bringing diverse patient perspectives to drive 
innovation within AstraZeneca as we work to 
improve the entire patient experience with 
‘whole disease’ solutions
At AstraZeneca we strive to meet the diverse 
needs of patients around the world. Our Health 
Innovation Hub models exist across Europe 
and emerging markets (Asia, Latin America 
and Middle East and Africa areas).
Learn more about our commitment to patients 
and Health Innovation Hubs on our website.
Disease prevention and treatment continued
Sustainability in action
A hackathon event at 




with type 2 diabetes will 
potentially be impacted 
by Take CaRe of Me.
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Disease prevention and treatment continued
 Highlight
ACT on Heart Failure (HF)
The Accelerate Change Together (ACT) initiative 
aims to extend and improve the lives of HF patients. 
The programme's long-term targets include: cutting 
hospitalisationsforHFbyhalfandimprovingfive
year survival rates by 20% by 2024. We have over 
40 local ACT on HF country teams in Latin America, 
Europe, Asia, Africa and North America. 
Challenges
There were challenges in 2020 for patients 
accessing treatment for NCDs due to 
the pandemic, including pressures on 
healthcare systems, mobility limitations and 
prioritisation. This has highlighted the need 
for greater health system resilience. There are 
reputational risks and opportunities based upon 
the quality of our response to public health 
emergencies such as the COVID-19 pandemic. 
Sustainability in action
Partnering with World Heart 
Federation for cardiovascular care
AstraZeneca and the World Heart Federation 
(WHF) launched a partnership to drive global 
action to prevent, control, and reduce the 
burden of cardiovascular disease and associated 
complications. This partnership represents an 
important step in realising our ambition for our 
medicines to protect the lives of 50 million people 
whosufferfromcardiovascular,renalandmetabolic
diseases. WHF is the world’s leading voice for 
cardiovascular health on global policy, advocacy 
and disease awareness initiatives, representing the 
interestsofheartfoundations,scientificsocieties,
civil society and patient organisations from over 
100 countries.
This partnership focuses on two 
main objectives: 
 Progress evidence-based policy solutions, 
with a strong focus on heart failure
 Increase the level of awareness on the 
burden of cardiovascular diseases worldwide 
In 2020, AstraZeneca worked with the WHF to: 
• Launch Spotlight on Heart Failure, a global 
campaign to raise awareness of the signs and 
symptoms of HF and encourage healthcare 
professionals to initiate discussions with 
at-risk patient groups
• Inspire policy change through the 
Heart Failure Gap Report a global survey 
evaluating attitudes about heart failure among 
the general public and policymakers
• Invest in the WHF Salim Yusuf 
Emerging Leaders Programme, an international 
training programme on cardiovascular 
health policy research, health systems and 
implementation science
This partnership represents 
an important step in realising 
our ambition for our medicines 
to protect the lives of 
50 million people 
who suffer from cardiovascular, 
renal and metabolic diseases.
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Why it matters
We must continually innovate 
and take a long-term perspective 
to address current and future 
public health needs. AstraZeneca 
has a role to play in contributing 
to equity in our society through 
access to healthcare, clinical trials, 
healthcare delivery and more.
Non-communicable diseases (NCDs) are the 
greatest cause of death worldwide.1 We know that 
evenaswestrivetousethemosteffectivemeans
to reach as many people as possible, we have a 
long way to go. Responsible R&D makes business 
sense because it drives us to innovate, establish 
new and expand existing partnerships, venture into 
new markets and develop new medicines in a way 
that advances health equity. 
 Description
Company stewardship in the development of a 
responsible product portfolio strategy to drive 
global health outcomes, e.g. addressing unmet 
medical needs, investing in neglected diseases, 
and embedding environmental predictors of disease 
state,especiallytoimprovetheaccessandefficacy
of medicines for vulnerable populations.  
 Approach
Cross-functional pipeline governance teams 
meet to develop an innovative product portfolio 
that drives positive global health outcomes to: 
Address unmet medical needs and barriers 
to patient experience
Increase the speed and breadth of 
patient access
 Drive excellence in product life cycle 
management
Understand long-term impacts of 
scientificadvances
In 2020 we made a commitment that our clinical 
trials represent the diversity of the communities 
with the relevant disease. As a science-led, 
patient-focused organisation, we have an obligation 
to play our part in addressing health inequities 
and eliminating discrimination from the delivery 
of healthcare.
We also progressed our Digital Health R&D 
approach, which focuses on developing novel 
digital solutions that harness the power of data 
and analytics to transform medicines development 
and improve patient outcomes and experience. 
Learn more on our website.
In 2020, we worked to advance our approach 
and identify innovations, aiming to: 
• Consider diverse geographical selection for 
clinical trial development, including low- and 
middle-income countries
• Provide early access and continued post-trial 
access for clinical trial participants
• Collaboratetoadvancescientificunderstanding
and build local capacity for R&D
• Considerhowourproductswillaffectthe
populations they intend to treat within the 
R&D phases, through our work on product 
safety and Product environmental stewardship
• Consider the range of ethical patient 
access issues that arise from biological 
and medical science
Responsible R&D is closely related to other 
areas of our sustainability strategy, such as 
Affordability, Investments in health systems, 
and Ethical business culture, including Bioethics.
Responsible research 
and development
Our work contributes to these 
Sustainable Development Goals:
SDG 3 | Good health and wellbeing 
SDG 17 | Partnership for the goals
We're progressing 
our Digital Health R&D approach, 
which focuses on developing 
novel digital solutions that harness 
the power of data and analytics to 
transform medicines development 
and improve patient outcomes 
and experience.
A colleague in Guadalajara, Mexico 
working on Digital Health.
In 2020 we made a 
commitment that our 
clinical trials represent 
the diversity of the 
communities with the 
relevant disease. 
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Diversity in clinical trials  
We are taking action to ensure that our clinical trials 
represent the diversity of the communities with the 
relevant disease. Our actions include: 
• Developing ways of using internal and external 
data sources to establish clinical trial diversity 
data baselines and identify gaps 
• Expecting consideration of patient insights 
and disease population diversity early in 
project planning 
• Clarifying criteria for reimbursement of lost work 
time to remove barrier to trial participation
• Initiating training for new and diverse investigators
• Characterising our key opinion leaders, patient 
interest groups and advisory boards to help align 
to our representation objectives
• Building alliances within key communities and 
within the industry. In 2020, AstraZeneca's Chief 
MedicalOfficerjoinedtheExecutiveCommittee
of the Multiregional Clinical Trial initiative at 
Harvard University, which is working on an 
inclusion and diversity toolkit for clinical trials. 
A guidance document was released to help 
pharmaceutical companies achieve diversity, 
inclusion, and equity in clinical research, 
along with a set of useful toolkits for clinical 
trial diversity 
For more on our approach to ensuring all that we do 
reflectsthediversityofthecommunitiesweserve,
see Inclusion and diversity.
Harnessing digital to optimise 
the patient experience  
Digital health is the point at which healthcare, 
technology, data and analytics converge. The 
WorldHealthOrganizationbelievesdigitalhealth
has the potential to improve health for everyone.2 
Here are two examples of our digital health work: 
Clinical trials
We aim to increase access for underserved 
communities by using digital technologies. One 
of the challenges of study participation for patients 
is the amount of time spent attending clinic visits. 
With virtual visits, non-invasive data collection and 
technology that monitors patients in their homes 
instead of in a hospital setting, we are reducing 
the number of clinic visits needed. We are scaling 
this model globally across our therapy areas and 
implementing strategies that aim for the majority 
of our clinical trials to be hybrid — partially 
in-person and partially virtual.
Digital therapeutics
As we move forward, the use of devices and 
sensors to remotely monitor patients should 
reduce by half the incidence of acute hospital 
visits across all our therapy areas. Our vision 
is to reimagine healthcare by delivering better 
outcomes using digital therapeutics (DxTx). 
In 2020, we developed an innovative DxTx 
aimedatsupportingearlieridentificationand
management of Interstitial Lung Disease (ILD). 
ILD is an umbrella term for a wide range of 
conditionsthatcausescarring(fibrosis)ofthe
lungs, impacting the patients’ ability to breathe. 
The new DxTx is intended to enable the early 
detection and management of ILD. 
Greater access to children's 
cancer medicines
The AstraZeneca Paediatric Oncology Working 
Group was established to set objectives to 
address unmet medical needs in paediatric 
oncology. In 2020, the group established 
partnerships with Children’s Oncology Group and 
Innovative Therapies for Children with Cancer in 
Europe (ITCC) to ensure AstraZeneca delivers 
optimal paediatric studies, while securing pivotal 
access to the rare and vulnerable paediatric 
population. The Group's internal engagement 
with project teams aims to raise awareness of the 
need to accelerate initial paediatric evaluation of 
AstraZeneca’s cancer medicines.  
" Developing appropriate medicines is absolutely 
critical for paediatric patients. And I'd urge 
everyone to build this thinking into their project 
strategies early, and challenge the norm and 
make this the new normal."  
—  Eileen McBride, Project Leader, 
Intelligent Pharmaceuticals
Responsible research and development continued
Sustainability in action
 Highlights
AstraZeneca CEO signs historic 
vaccines pledge 
In collaboration with nine biopharmaceutical 
companies, Pascal Soriot signed a pledge to 
continue to develop and test potential vaccines 
for COVID-19 in accordance with high ethical 
standardsandsoundscientificprinciples.
Research on treating and 
preventing COVID-19 
We are studying preventative options for 
people exposed to COVID-19, as well as to 
treat and prevent disease progression in patients 
already infected with the virus. See more in 
COVID-19 actions.
Accelerating patient access to 
our medicines
AstraZeneca implemented a project to identify 
changes needed to submit for approval in 
international markets at a rate 50% faster than 
previously.Acceleratedfilingtimesshouldresult
in patients receiving our life-changing medicines 
sooner. This project aims to increase the speed to 
fileinmultiplecountriesontheAccesstoMedicines
Index(ATMI),includingBrazil,China,Colombia,
Egypt, India, Indonesia, Iraq, Mexico, Philippines, 
South Africa, Thailand, and Vietnam.
Challenges
The pandemic had an impact on initiation, 
ongoing recruitment and follow-up in some 
clinical trials, primarily in the early stage. 
We believe it remains prudent to assume that 
additional delays will arise as a consequence 
of the pandemic.
Digital health is 
the point at which 
healthcare, technology, 
data and analytics 
converge.
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Why it matters
The planet's health is our health. 
The relationship between our 
health and the planet's health is 
circular, with humans and nature 
impacting each other. We are 
dependent upon nature for healthy 
air, water, soil and overall climate. 
We must minimise our impact 
on nature so that we continue 
to support a healthy future. 
As a healthcare company, we have a responsibility 
to raise awareness of the interdependence between 
the health of our planet and the health of people. 
By fostering healthy environments, prevention and 
mitigationeffortscontributetohealthierpopulations
andcanalsobenefitthehealthcaresystems
our business relies upon by helping control the 
incidence of disease on a global scale. 
TheWorldHealthOrganizationestimatesthat
nearly 14 million people die each year as a result 
of living or working in an unhealthy environment, 
including eight million people from air pollution 
alone.1 The climate crisis poses risks to public 
health, with rising global temperatures now 
accelerating respiratory and cardiovascular disease, 
food insecurity, changes in water-borne and 
vector-borne illnesses, increasing allergens, 
aswellasmentalhealtheffects.Peoplein 
low- and middle-income countries are 
disproportionately impacted, which exacerbates 
pre-existing inequalities of disadvantaged groups.2
 Description
Companyeffortstopreventdiseaseandimprove
health outcomes by addressing environmental 
determinants of health. These determinants include 
climate change, air and water quality, the built 
environment, and the environmental dimension 
of antimicrobial resistance (AMR). 
 Approach
Our approach recognises that the health of 
our planet and the health of people are intrinsically 
linked. We address our environmental impacts 
from the beginning of our research process all the 
way through to cross-sector collaborations for 
improved health of people and the planet. 
We know that the benefits from reducing 
our environmental footprint can take effect 
within a few years of reducing emissions 
and modifying environments. This can in 
turn help prevent certain diseases,3 such 
as chronic obstructive pulmonary disease, 
lung cancers, stroke and heart disease.
In 2020, we committed to health equity 
— to ensuring that everyone has an equal 
opportunity to be as healthy as possible, by 
removing barriers to access and eliminating 
discrimination from the delivery of healthcare. 
This compels us to consider health disparities 
facedbypopulationsdisproportionatelyaffected
by pollution and unhealthy environments.
Pipeline
Increasing our understanding of 
environment’s impact on health in 
relation to our therapy areas
Production
Driving improved environmental 
performance of our operations for 
measured impact on human health
Products
Life cycle considerations of human 
health impacts for manufacture, use 
and disposal of our products
Programmes
New programmes and scaling existing 
programmes to improve human health 
through a healthier environment
Partnerships
Cross-sector collaborations and 
research for environmental health 
indicators and outcomes
Environment's impact on health Our work contributes to these Sustainable Development Goals:
SDG 3 | Good health and wellbeing 
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Research on connection between 
air quality and diseases in Uganda
Outdoor air pollution accounts for an estimated 
4.2 million premature deaths per year,4 creating 
asignificantburdenonpublichealthsystems.
InUganda,publicawarenessontheeffectsof
air pollution is low,5 despite evident high levels 
of outdoor air pollution. In partnership with the 
Cambridge Institute for Sustainability Leadership 
(CISL), AstraZeneca launched a new research 
fellowship to explore strategies to reduce outdoor 
air pollution in Uganda and promote healthy 
communities through evidence-based policies. 
A CISL fellow will collect data in two locations 
in Uganda (Kampala, and Jinja) and compare 
strategies in these locations to air quality 
managementeffortsinotherAfricancitiesand
London. This study aims to create a platform 
for knowledge sharing among stakeholders 
responsible for addressing outdoor air pollution 
in Uganda. The platform should increase the 
ability of health practitioners to manage the 
impact of air quality on respiratory, oncological 
and cardiovascular disease prevalence. This 
research will be developed with input from 
the Medical Research Council Epidemiology 
Unit at the University of Cambridge and the 
Global Public Health Research Programme at 
Makerere University, as well as other stakeholders 
across Cambridge and Uganda. Read more on 
our website.
Research on the environmental 
dimension of AMR 
Antimicrobial resistance (AMR) occurs when 
bacteria, viruses, fungi and parasites evolve 
over time and no longer respond to medicines. 
This makes infections harder to treat and increases 
the risk of disease spread, severe illness and death. 
Asaresult,medicinesbecomeineffectiveand
infections persist in humans, increasing the risk 
of spread to others.7 
In 2020, AstraZeneca and other scientists 
published a paper that found the current 
understanding of safe antibiotic levels in rivers 
may not prevent evolution of antibiotic resistance 
and fully protect human health. This research 
suggests the need to introduce thresholds to 
help address the spread of resistant bacteria. 
This paper is part of AstraZeneca's commitment 
to the United Nations Roadmap on Antimicrobial 
Resistance. In addition, AstraZeneca published 
a novel approach called ‘SELection End points 
in Communities of bacTeria’ (SELECT) to include 
the selection potential for AMR within the 
environmental risk assessment of antibiotics. 
AstraZeneca also funded and co-authored 
research on antibiotic residues in sewage 
andagriculturalrun-off. This focused on the 
development of a novel method to establish 
safe release limits for antibiotics that could 
also help to identify highly-contaminated areas 
throughenvironmentalsurveillance.Thefindings
are being used in the United Kingdom to advocate 
for environment-related recommendations to 
beaddedtothegovernment'sfive-yearaction
plan on AMR. 
Environment's impact on health continued
 Highlights
Turning waste into clean energy
In collaboration with Cambridge Institute for 
Sustainability Leadership (CISL), biodigesters 
installed for the Dunga Beach pilot project on Lake 
Victoria in Kenya are being maintained to monitor 
the transformation of waste into clean energy and 
reduce exposure to air pollution from cooking 
stoves in the surrounding community.
Investing in people- and 
planet-healthy buildings 
Designing workplaces that promote health for 
people and the environment is important to us. 
We adopt appropriate external environmental 
assessment tools in order to optimise environmental 
design for future buildings. Three of our sites are 
locatedinbuildingscertifiedbyLeadershipin
Energy and Environmental Design (LEED): 
Gaithersburg,US;Prague,CzechRepublic;
and South San Francisco, US.
Sustainability in action
Air pollution added as focus 
to the YHP
Many non-communicable diseases (NCDs) 
areinfluencedbyasetofriskfactorsrelatedto
the environment where we live. Approximately 
70% of premature deaths from NCDs can 
be linked to behaviours that started in 
adolescence.6 Our Young Health Programme 
(YHP) works to help young people take control 
of their health and prevent NCDs. In 2020, 
we set and met our goal to have all new country 
programmes with our partner Plan International 
include air pollution as a focus. Learn more 
about the YHP on our website.
Challenges
Global dialogue and action to combat the 
climate crisis, along with the devastation of the 
COVID-19 pandemic, have brought into sharper 
focus the consequences of the environment’s 
impact on health. Global risks are acutely 
felt, and local risks can quickly go global. As 
we look to the future health of the planet and 
people, we should work to increase resilience to 
future shocks with our partners. 
" The purpose of this project is to study the interconnectivity between environmental 
health and disease with a view to helping foster healthier and safer communities. 
I’m delighted to lead this project which has the wider ambition to raise public 
awareness of air pollution exposure and inform stakeholders across African cities 
when formulating evidence-based policies addressing outdoor air pollution, as well 
as guiding health professionals when interpreting air quality data in the management 
of patients with respiratory disease." 
—  Dr Gabriel Okello, Prince of Wales Global Sustainability Fellow, CISL
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Why it matters
Health disparities exist in 
all healthcare systems — 
with marginalised populations 
disproportionately impacted 
in both developed and 
low- and middle-income 
countries. Widespread 
collaboration is needed to 
create the system-wide changes 
necessary to address health 
disparities and ensure that 
everyone receives equitable, 
quality healthcare.
As a healthcare company, we are committed to 
health equity — to ensuring that everyone has an 
equal opportunity to be as healthy as possible, 
by removing barriers to access and eliminating 
discrimination from the delivery of healthcare. 
We also seek to make health systems more 
resilient to withstand future crises.  
Our investments support patients on their path to 
wellness. They enable us to gain a more intimate 
understanding of global, regional and local health 
challenges so that we can address gaps by 
developing targeted medicines and treatments.
 Description
Company contributions to strengthening healthcare 
capabilities and infrastructure — including in 
developing and emerging markets — to facilitate 
access to healthcare and improved quality of 
healthcare and outcomes.   
 Approach
The nature of diseases and infection and their 
risk factors call for multi-sector involvement in 
prevention and control measures. We work with 
stakeholders to align on our shared objectives and 
develop interventions that are optimised to address 
local challenges, while leveraging our experience in 
health programming. 
We aim to build the capabilities of healthcare 
systems to best respond to patient needs by:
Remaining culturally relevant and ensuring 
programming is locally appropriate 
Using our global footprint to scale partnerships  
Establishing mechanisms for collaboration 
with our partners, for example through 
joint coordination, planning, follow up and 
agreement of a set of core indicators for 
monitoring and evaluation
In 2020, we launched The Partnership for Health 
System Sustainability and Resilience (PHSSR) 
with the London School of Economics (LSE) and 
the World Economic Forum (WEF), motivated by a 
shared commitment to improving population health, 
through and beyond the COVID-19 pandemic. 
Change is needed to build health systems that are 
both resilient to crises and sustainable in the face 
of long-term stresses. From new models of care, to 
innovativefinancingmechanismsandbreakthrough
technologies, PHSSR aims to make change 
happen, by identifying transferable solutions with 
the greatest potential, and supporting their adoption 
to deliver better health and better care for all.
 Read about our approach to 
health systems resilience.
 Key targets and progress
Investments in health systems
2025 target
Reach 50 million 
people through our 
access programmes, 
including: Healthy Heart 
Africa, Young Health 
Programme (YHP), 





More than 25m people 
reached (cumulative). 
This target has been 
modifiedtodoublethe
people reached and now 
encompasses four Access 




to strengthen health 
systems throughout 
the world through 
our Healthy Heart 
Africa, Healthy Lung, 





More than 132,000 
healthcare workers trained 
(cumulative). The previous 
target of 75,000 was 
achieved in 2019.
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to these 
Sustainable Development Goals:
SDG 3 | Good health and wellbeing 
SDG 17 | Partnership for the goals
Healthy Heart Africa launch event in Uganda.
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respiratory. Our investments in health systems 
are aligned to these therapy areas, to ensure 
connection to our overall company strategy 
and business model. The stories below outline 
2020 progress for each therapy area. 
  Respiratory 
Redefining care for severe asthma patients 
across the globe  
Withmorethan34millionpeopleaffectedby
asthma worldwide,2 we have made a long-term 
investment to improve severe asthma patient care 
through our PRECISION programme. PRECISION 
brings together leading experts in asthma and 
healthcare policy to ensure severe asthma patients 
routinely receive the right care, at the right time, 
inthemostappropriatesetting.Oureffortsare
focused on accelerating appropriate referrals to 
specialists, building capability and capacity and 
improving policy and access. Launched in 2017, 
PRECISION operates across 56 countries and with 
the involvement of more than 160,000 healthcare 
professionals — transforming clinical standards 
and patient referral pathways and identifying 
patients most at risk based on potential 
over-reliance on oral steroids.
Africa Pumua Initiative
Launched in 2020, Africa Pumua aims to improve 
paediatric and adult asthma management 
across healthcare sectors in Ghana and Kenya, 
in partnership with governments and healthcare 
professional societies. The initiative forms part of 
our commitment to deliver improved accessibility 
and availability of quality care in Africa.
  Cardiovascular
Healthy Heart Africa pivots to address COVID-19 
In Sub Saharan Africa, cardiovascular diseases 
(CVD) are the most frequent causes of 
non-communicable disease (NCD) deaths, 
responsible for approximately 13% of all deaths 
and 37% of all NCD deaths.1 Our Healthy Heart 
Africa (HHA) programme contributes to the 
prevention and control of hypertension and 
decreasing the burden of CVD across Africa. 
Currently in its 6th year of implementation, 
HHAispresentinfivecountries—Kenya, 
Ethiopia,Tanzania,GhanaandUganda.
Many of our Access to healthcare programmes 
have been impacted by the pandemic. In line with 
our Values to do the right thing and put patients 
first,weaskedourHHApartnerstosuspend
routinecommunityactivitiesandofferedsupport
to them, their healthcare facilities and the local 
communities. We proposed that our partners 
reallocate their programme budget towards safety 
measures and personal protective equipment 
such as masks and gloves. We also supported the 
Kenyan Ministry of Health, providing them with a 
platform to distribute COVID-19 materials to their 
healthcare facilities. Together we invested funds to:
 Raise awareness of how to limit the spread 
of the virus
 Protect those on the clinical front line in 
community health
Project Heartbeat in India
Launched alongside Tricog Health, this project 
addresses local demand for early diagnosis and 
intervention for heart attack patients, by enabling 
cloud-basedartificialintelligencediagnosisof
electrocardiograms (ECGs), routing patients to 
the nearest Cath Labs, and allowing for accurate 
diagnosis, ultimately improving patient outcomes. 
Todate,2,195ECGshavebeenconducted;
922 abnormal cases have been detected from 
which112criticalMIswereidentified,referred
and treated — all within an average diagnosis 
time of two minutes.
  Oncology
Investing to transform cancer care 
Lung cancer is the leading cause of cancer-related 
death.Approximatelyoneinfivepeoplearealive
fiveyearsafterinitialdiagnosis.3 We have an 
ambition to change these statistics and eliminate 
cancer as a cause of death. In 2019 we joined the 
Lung Ambition Alliance to collaborate with peers 
andpartnerstofindthebestpossiblesolutionsfor
lung cancer patients. In 2020 the Alliance launched 
the Lung Cancer Care awards, inviting patient and 
caregivernon-profitorganisationstosubmitgrant
applications for projects that go beyond prevention 
tosupportpeoplewithlungcanceratdifferent
stages of diagnosis. The initiative recognises the 
veryspecificlocalbarrierstoqualitycarethatmust
be considered when developing patient centric 
solutions. The Alliance awarded 13 organisations, 
representing six countries, that seek to transform 
cancercareatdifferentpointsalongthelung
cancer patient experience.  
Investment in health systems continued
 Highlights
Donation of 10,000 blood pressure monitors
In alignment with the South African National 
Department of Health's vision of task shifting to 
community health workers, AstraZeneca donated 
blood pressure monitors to support screening 
of NCDs.
Phakamisa oncology programme renewed
In partnership with the South African National 
Department of Health, Phakamisa aims to support 
implementation of the National Cancer Campaign 
which seeks to address awareness, early diagnosis 
and access to care for breast and prostate 
cancer patients. 
Early cancer screening programme in India
The Ganga Godavari programme focuses on 
specialised cancer screening for oral, breast 
and cervical cancer. It creates awareness through 
community health education activities and follow-up 
processestoensureeffectivehospitalreferralsfor
cancer patients and their treatment. Since its launch 
in2019,4,000beneficiarieshavebeenscreened.
Challenges
We are aware of the challenges that some 
markets face with regards to their healthcare 
gaps and that their journey to resilience may 
not be realistic in the near-term. In 2020, 
we adjusted our programmes to meet local 
needs related to COVID-19. 
Sustainability in action
Our Healthy Heart Africa partners in Kenya — 
the Kenyan Conference of Catholic Bishops (KCCB) 
— host COVID-19 awareness events.
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Why it matters
AstraZeneca is committed to 
driving equitable access to 
medicines for patients globally. 
Our medicines help address 
unmet medical needs, improve 
health and create economic 
benefits. We must work on 
affordability today to ensure 
that in the long-term, patients 
can access our medicines, 
and there are resources and 
infrastructure available to 
purchase and distribute our 
medicines equitably. 
Industry, policy makers and payers need to 
work together to create a more resilient health 
system, and to develop solutions to pay for 
the value of medicines while addressing global 
variationinaffordability.
Byworkingonaffordabilitysolutionsforpatients
and payers, we can ensure that our medicines are 
made available and that we focus on delivering 
treatmentsthataretargetedandeffectiveto
meet patient needs. This can help to lower 
healthcare costs by preventing more serious 
and costly diseases and reducing the need 
for more expensive care.  
 Description
The company’s position, policy and performance 
on the pricing of medicines, including core 
pricing principles, tiered pricing, and access 
andaffordabilityprogrammes.
 Approach
We understand that a medicine’s value within a 
particularhealthcaresystemisunique,withdifferent
healthcare costs, patient populations and societal 
priorities across each health system. Our approach 
is therefore driven by the belief that the price of a 
medicineshouldreflectitsvalue,maximisepatient
access,andprovideflexibilitytoaccommodate
variation in global health systems and economic 
realities for patients. 
We apply value-based agreements (VBA)1 to hold 
ourselves accountable and ensure patients are truly 
benefitingfromourproducts.VBAisanagreement
that reduces uncertainty of payers (economic or 
clinical) where access, reimbursement or price 
islinkedtorealworldclinicalbenefit.
We work closely with healthcare systems, payers 
and policymakers, with the aim of improving 
health system resilience and to ensure access is 
widespread. We strive to support equitable access 
to healthcare globally by:
Coordinating programmes with country health 
systems to deliver medicines in a locally 
affordablecontextforpatients
Supporting infrastructure, for example training 
healthcare professionals and facilitating clinics 
for screening and diagnosis
Delivering programmes which focus on making 
medicines available through donation to eligible 
patients (i.e. free of charge)
Tailoring payment models, including tiered 
pricing (based on gross national income) 
and value-based agreements
 Read more in our Affordabilitystatement.
Affordability
    See Sustainability Data Summary 
for Affordability figures.
By working on affordability 
solutions for patients and 
payers, we can ensure that our 
medicines are made available 
and that we focus on delivering 
treatments that are targeted and 
effective to meet patient needs.
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Affordability continued
Access and affordability programmes 
Many people around the world face barriers to accessing medical treatment and healthcare. Some lack 
insurance or do not have the ability to pay for medicines. Some live in medically underserved communities. 
Some need to choose between paying for healthcare or paying for food. The issues are complex. We 
haveofferedaccessandaffordabilityprogrammestopatientsformorethan36yearsincountriesallover
the world. These programmes are designed in partnership with local health systems to help patients gain 
access to the medicines and healthcare they need.
Ouraccessandaffordabilityprogrammesareavailabletopatientswhomeettheeligibilityrequirements.





and who meet certain eligibility requirements. 
Our largest PAP is AZ&Me in the US. AZ&Me is 
governed as a 501(c)4 organisation, operating under 
a strict regulatory structure for the purpose of social 
support and is separated by this structure from our 
commercial business. In 2020, we donated more 
than $1.6 billion in medicines through AZ&Me to 
patientswhocouldnotaffordtopay.
Reducing costs in emerging markets
We have a variety of patient access programmes in 
emerging markets, each tailored to meet the needs 




discounts for patients, providing access across 
the country and aims for treatment adherence. 
FazBemisavailablein27,000pharmaciescovering
allBrazilianstates.In2020,weenrolled277,000
new patients, and reached 642,000 patients with 




partners who support patients in medically 
underserved communities, humanitarian settings 
and/orthroughdisasterreliefefforts.In2020,we
donated $12 million of medicines to Americares 
for use in their Free Clinic network in the US. 
This network improves the health of people living 
in or near poverty, by providing no- or low-cost 
care. We also donated $15 million of oncology, 
respiratory, metabolic and cardiovascular medicines 
to Direct Relief to facilitate a rapid response in 
times of crisis. These medicines were redistributed 
to Haiti, El Salvador and Myanmar as part of 
COVID-19reliefefforts.
While we recognise that donating medicines 
is not a long-term solution in isolation, it is 
an option to address an immediate need and 
we remain committed to working with health 
system stakeholders and payers towards 
more systemic solutions.
Value-based agreements 
Value-based agreements are designed to enable 
timely patient access while reducing uncertainty 
of payers (clinical or economic), ultimately to 
improve patient outcomes and health system 
effectiveness.In2020,weworkedcloselywith
a European government to create an outcomes-
based agreement for a medicine that treats severe 
asthma. This agreement links reimbursement to 
real-world data, thereby ensuring that only patients 
whoreceiveabenefitcontinuetreatmentandthat
the health system only reimburses AstraZeneca for 
these patients. 
We have entered into over 100 innovative value-
based agreement partnerships, across our three 
main therapy areas. The number of contracts has 
more than doubled versus 2019. We anticipate 
value-based agreements will continue to increase 
to ensure timely access for patients. We will 
continue to invest in partnerships to support data 
collection system design and to demonstrate the 
real-world value of our medicines.
Sustainability in action









access and competitive pressures' is an 
AstraZeneca principal risk with the potential 
to have a material impact on our business 
or results of operations, as described in 
our Annual Report. 
We operate in more than 100 countries around 
the world, which means we are subject to 
political,socioeconomicandfinancialinfluences
from each of those geographies, as well as from 
the perspective of a global company. There can 
be additional scrutiny from governments and 
healthcare systems on the price of medicines, 
for example in response to broader economic 
pressures.Thiscanimpactourfinancial
performanceandthereforehaveaneffectupon
the scale of investment we can make in the 
discovery and development of new medicines.
 Highlight
Increasing access for breast cancer 
patients in rural Cambodia 
In 2020, we celebrated the 12th year of our 
collaboration with Americares and the Sihanouk 
Hospital Center of Hope (SHCH) for the Cambodia 
Breast Cancer Initiative. This programme aims to 
increase early diagnosis and treatment for women 
living in rural areas. In 2020, the programme 
administered more than 18,500 units of donated 
AstraZeneca medicines to post-menopausal breast 
cancer patients. Since the programme began, 
more than 4,200 patients have received treatment.
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for a clinical trial
60% 
reduction in 









94% of discharges 











    See Sustainability Data Summary for full metrics and methodology.
SDG 12 | Responsible consumption and production
SDG 13 | Climate action
SDG 17 | Partnership for the goals
Connection to health:
Supporting a healthy 
environment helps prevent the 













The health of the planet 




proactively manage our 
environmental impact 






Contributing to the 
Sustainable Development Goals, 
a universal blueprint for prosperity 
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The relationship between our 
health and the planet's health 
is circular, with society and 
nature having a huge impact on 
one another. The effects of the 
continued growth of the global 
economy and its reliance on 
fossil fuels are putting at risk 
not only human health, but 
also the ability of the Earth to 
sustain life. We must innovate to 
ensure sustainable growth that 
doesn’t compromise the natural 
resources upon which we all rely, 
and which underpin societal and 
planetary health.
To sustain life on Earth, we must work within the 
systems that nature evolved, and the human formed 
systems of society and business. Global society 
is depleting the Earth's natural capital — such as 
water, forests and biodiversity — at rates faster than 
nature can replenish. Pollution takes a heavy toll on 
humanhealth,reflectedbyanestimatedninemillion
premature deaths globally.1 We are taking action 
now because we recognise the inextricable link 
between a healthy planet and healthy people. 
The big picture
Addressing the climate crisis is the century’s 
greatestglobalhealthopportunity;2 it's also an 
opportunity to address systemic inequities. As an 
organisation committed to health equity, climate 
action is central to our sustainability strategy 
becauseclimatechangeamplifiesandaccelerates
existing social inequities, including physical and 
mental health issues, poverty, forced migration, and 
disparities in education, housing, wealth, etc. 
COVID-19hasdemonstratedthesignificant
negative impacts that result from humans living out 
of harmony with nature. Deforestation, biodiversity 
loss and development activities such as agriculture 
and urban sprawl have increased the risk of 
transmissionofzoonoticinfectiousdiseases,such
as COVID-19, from animals to humans.3 Addressing 
the root causes of the pandemic presents a unique 
opportunity to transition towards an economy 
centred around people and nature.
Most of AstraZeneca's environmental impact is 
embedded in our products and the goods and 
services we purchase, rather than at our sites. 
There is increasing scrutiny of the environmental 
footprint of medicines and there are signals of 
change towards the procurement of medicines with 
a smaller footprint. Over the next decade we expect 









Pharmaceuticals in the environment 
Water stewardship
Waste management 
See Environment’s impact on health for more 




• Product environmental stewardship: 
Developed internal Product 
Sustainability Index
• Greenhouse gas reduction: 
Launched Ambition Zero Carbon
• Pharmaceuticals in the environment: 
Initiated IMI PREMIER project
• Water stewardship: Ranked on CDP A list
• Waste management: Founding member 
of the Circular Bioeconomy Alliance and 
co-author of 10-point action plan for the 
circular bioeconomy
Maximising our positive 
environmental impacts and 
minimising our negative impacts, 
while improving health outcomes
Working in harmony with society 
and the natural environment, 
embracing a more circular mindset 
to how we innovate
Decoupling our growth from our 
use of natural resources
We envision a future where we help 
restore our planet to health by: 
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Governance 
Environmental matters are managed by the 
Executive Vice-President (EVP), Sustainability 
andChiefComplianceOfficer,whoreportstothe
CEO. Implementation is conducted in partnership 
with key functions including Operations and 
Oncology and BioPharmaceuticals R&D. In 2020, 
a Global Head of Environmental Protection was 
appointed for implementation and delivery of our 
environmentalprotectionstrategy.Ourunified
quarterly scorecard tracks 16 Environmental 
protection metrics and communicates our 
performance to all employees.
In 2020, we established an Ambition Zero Carbon 
Governance Group with executive-level ownership, 
accountable for the delivery of Ambition Zero 
Carbon. The group meets monthly and includes 
our CEO, CFO, the EVP, Sustainability and Chief 
ComplianceOfficer,andtheEVP,Operations
and IT. A Taskforce on Climate-related Financial 
Disclosures (TCFD) steering group was also 
established with cross-functional membership 
to identify and proactively manage the physical 
and transitional risks and opportunities posed to 
AstraZeneca by climate change. 
The guide for our environmental management 
system (EMS) — our global safety, health and 
environment (SHE) management principles 
— is embedded in our Code of Ethics. A SHE 
management system is implemented in line 
with recognised international standards 
e.g. ISO 14001 and 50001.
Key parts of our EMS include:
• Mandatory standards for activities that can cause 
environmental harm
• Risk management system to control change and 
local risk registers
• An enterprise OneSHE Advisory board with 
representation from SHE leads at strategic sites
• Annualmanagementsystemreviewsignedoffby
site leads and evaluated at an enterprise level
• Audit programme, led by an independent 
organisation, with auditors from across the 
business trained in auditing to ISO standards, 
reporting back to functional leads and the 
Audit Committee and more4
To drive our climate action initiatives and meet 
our environmental targets, we have a dedicated 
fund managed by a Natural Resources Reduction 
Governance Group (NRRGG). This fund has 
invested more than $100 million in environmental 
efficiencyinnovationssince2015,including
$19 million for 42 new projects in 2020. We use site 
water scarcity assessments and natural resource 
audits to identify opportunities for management 
and investment. In 2020, seven sites were internally 
assessedforefficiencyopportunities.
Taskforce for Climate-related Financial 
Disclosure (TCFD)
As part of Ambition Zero Carbon and our 
progress on climate resilience, we are publishing 
ourfirstvoluntarydisclosureinlinewiththe
recommendations of TCFD. Our intention is to 
demonstrate how we consider the impact of climate 
change issues on our business and integrate 
climate-related risk and opportunities into our 
governance, risk management and strategies. 
See the AstraZeneca TCFD disclosure statement 
within our Annual Report. 
COVID-19 Impacts
We remained steadfast to our environmental 
commitments throughout the pandemic. 
We have advocated for a 'rebuilding better' 
approach. We became signatories to several 
landmark public-private sector initiatives including: 
Uniting to Recover Better;andRace to Zero. 
Environmental protection overview continued
$100 million 
invested by NRRGG fund 
in environmental efficiency 
innovations since 2015, including 
$19 million for 42 new projects 
in 2020.
We recognise that several of our annual 
Environmental protection measures were 
impacted by the pandemic and may 
not reflect a typical trajectory.






•  Gothenburg and Södertälje, Sweden 





(representing 26% of total 
energy consumption)
Some sites have sought external certification, including:
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Why it matters 
People and the planet benefit 
from medicines with the smallest 
possible environmental impact, 
while not sacrificing medical 
efficacy or safety. As technologies 
and healthcare systems evolve, 
so too should solutions to reduce 
energy, water, material use and 
waste generated from delivering 
medicines to patients.  
AstraZeneca is responsible for its choices in raw 
materials sourcing, manufacture and formulation 
of active pharmaceutical ingredients (APIs), and 
device and packaging selection. As we improve 
our processes, we can implement change ahead 
of evolving regulations, and lower costs of supply. 
This allows us to reinvest in life-changing medicines 
and improve patient access to healthcare solutions.
 Description
Companyeffortstoidentify,addressandminimise
the environmental impact of products from 
discovery in early R&D through development to 
launch of a new product and during its commercial 
lifetime to end-of-use.
 Approach
• Design out negative environmental impacts
•  Life cycle assessments to measure the 
environmental impacts of our products
•  Resource efficiency through targets to lower 
process mass intensity (PMI)
We manage the environmental impacts of our 
products from discovery in the lab all the way 
through to the end of a product's life. We evaluate 
all materials and processes used to make our 
products and our scientists proactively investigate 
opportunities to close the production loop and 
strive towards circular solutions across our 
product value chains.
We utilise life cycle assessment (LCA) 
methodology to measure the type and magnitude 
of environmental impacts that sit across our product 
value chains. We adhere to ISO LCA standards 
14040 and 14044 to ensure our environmental 
impact data are reliable, robust and relevant. This 
knowledge not only enables action to be taken 
to improve the environmental performance of our 
products, but also provides vital information on the 
type of investment required to embed sustainability 
in the value chains of our future medicines.  
While the pharmaceutical industry's absolute use of 
raw materials is relatively low in comparison to other 
industries, the conversion of those raw materials 
intoproductscanbeinefficient.Weuseametric
called process mass intensity (PMI) to measure 
ourrawmaterialefficiency.PMIismeasuredas
kilograms of raw materials used to produce a 
kilogramofthefinalAPI.AlowerPMImeanswe
areusingmaterialsmoreefficiently.Our2025target
for our small molecule drug projects is for 90% of 
new API production processes to meet PMI targets 
by launch. 
In 2020 we updated our two internal governance 
procedures that provide medicine development 
projects with a framework to complete key SHE 
activities such as environmental, process safety 
and occupational toxicology assessments and 
chemicalregistrationatdefineddevelopment
milestones. These ensure compliance and embed 
sustainability in our manufacturing processes prior 
to commercial manufacture.













We follow a 
life cycle approach 
that covers all stages 
of our products
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to these 
Sustainable Development Goals:
SDG 12 | Responsible consumption and production 








We set an internal 
PMI target for monoclonal 
antibody projects 
(our largest class of 
biological products).
2022 target
95% of paper-based 
product packaging 
materials used 





Progress was made 
towards the target 
of 95%. Learn more 
about our use of 
commodities linked 
to deforestation 
in our new 
Forestry Statement.
2025 target






Since 2015, 67% of 
projects (two of three) 
havemetdefined
resourceefficiency
targets. In 2020, a 
new oncology medicine 
met its PMI target at 
launch and we achieved 
a PMI reduction of 
9% across the late 
stage project portfolio. 
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Product environmental stewardship continued
Sustainability in action
Driving sustainability performance 
and product innovation
Many inputs from nature, such as water and raw 
materials, are needed across the pharmaceutical 
value chain to deliver our life-changing medicines. 
We need to dramatically reduce our resource 
consumption and minimise waste production 
in order to manage our environmental impact 
and achieve Ambition Zero Carbon. In 2020 
we developed and piloted an internal Product 
Sustainability Index (PSI) to advance product 
environmental stewardship performance and 
innovation across our therapy areas. Our goal is 
for all our products to be assessed against the 
PSI to track environmental sustainability — from 
development to launch and beyond — to inform 
environmental improvement plans for project teams. 
The PSI has scoring criteria across six categories: Improved quality of healthcare can 
lead to smaller GHG footprint
Our medicines are delivered to patients through 
healthcaresystems,whichcanbesignificant
contributors to greenhouse gas (GHG) emissions 
in the public sector. Increasingly, healthcare 
providers are looking at ways to deliver 
improved patient outcomes with a smaller GHG 
footprint, while at the same time responding to 
increasing demand upon healthcare services.
In 2020, we led new research to assess how 
improved treatment and management of common 
non-communicable diseases, such as asthma, can 
lead to a reduced GHG footprint of healthcare1. 
New data using real world evidence has 
demonstrated that up to 250,000 tonnes of CO2-
equivalent (CO2e) is released into the atmosphere 
every year in the United Kingdom alone from the 
overuse of reliever medication in the treatment 
of asthma, which is known to be associated with 
an increased risk of asthma attacks.2,3 Identifying 
opportunities to achieve better outcomes for 
people with diseases like asthma will reduce 
the environmental footprint of care and has the 
potential to be an increasingly important approach 
to more sustainable healthcare.
We participated 
in research with 
healthcare providers to 
assess how improved care of 
common non-communicable 
diseases, such as asthma, 
can lead to a reduced 
GHG footprint.
Carbon: greenhouse gas (GHG) 
footprint of a product across the whole 
value chain, per patient, per year
Power: percentage of renewable 
electricity, not including energy 
supplied for heating, used in 
manufacture across a product’s 
supply chain
Water (resource): water consumption 
across the whole value chain, per 
patient, per year 
Water (releases): risk of API discharges 
to the environment resulting from 
patient use and manufacturing (see 
Pharmaceuticals in the environment)
Resource use: use of raw materials 
in drug substance manufacture
Innovation and improvement: 
improvementsmadeacrossthefive
categories above, driven by innovative 
approaches during the product life cycle
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Green chemistry in the lab — 
Nature as inspiration for oncology medicine 
chemical development 
Nature is a source of inspiration for sustainability. 
In biology, plants employ photosynthesis to convert raw 
materials like water and carbon dioxide into chemical energy, 
usingtheenergyofsolarphotons.Theenergyefficiency
of photosynthesis is a concept considered in the 
Principles of Green Chemistry. Our process chemists 
apply green chemistry principles in their continuous search 
tofindbetterwaystodochemistryreliably,andinmore
sustainable ways. 
In 2020, a team of our scientists employed visible light 
photocatalysis — which uses blue light as the key source 
of energy — to drive the production of a key compound 
en-route to API. The team also substituted precious metal 
catalysts, regularly used in this type of reaction, with a 
non-metal catalyst that is readily available. This work 
representsoneofthefirstexamplesofalarge-scale 
proof-of-concept, when applying this technology to a 
complex API intermediate. This project is an important 
capability build for future API syntheses. Modern drug 
portfolios are moving away from largely planar chemical 
compounds, with more complex three-dimensional structures 
becoming commonplace. Visible light photocatalysis is a key 
enabling technology for the delivery of such structures.
Thesustainabilitybenefitsfromthisproject:
• Improvements to the chemistry, including waste, 
lower PMI and carbon footprint
 – 376% increased yield, thus providing more 
API per unit starting material
• Avoidingtheuseofmultiplehazardous 
reagents on large scale, reducing the overall 
safety risk of operating the process
• Decreased impact from precious metals extraction
Sustainability challenge
We held the second edition of the sustainability challenge 
run by our Pharmaceutical Technology and Development 
department in 2020. It focused on sustainable product 
innovation and raising awareness of sustainability. The 
challengeempoweredemployeesbyofferingseedfunding
for six winning groups to deliver sustainable solutions that 
align to our sustainability strategy and push the boundaries 
of science. The winning ideas included recyclable solvents 
forpeptidesynthesisandacarbon-zerostageforan
API synthesis.




In 2020, we committed to launch our next-generation inhaler to treat asthma and 
chronicobstructivepulmonarydisease(COPD)withnear-zeroGWPpropellantby2025.
Throughout 2020, we progressed a project spanning all key functions to investigate 
alternative low-GWP propellant options from an environmental, technical, regulatory, 
medical, non-clinical and commercial viewpoint.
First life cycle assessment (LCA) for clinical trials
WeconductedourfirstLCAforaclinicaltrialandcompletedstreamlinedLCAs
on three recently launched products in the oncology, cardiovascular, renal and 
metabolism (CVRM), and infection/vaccines therapy areas.
Mistra SafeChem project — safe and efficient chemistry by design
We became a partner and co-sponsor of the Mistra SafeChem project to enable 
and promote the expansion of a more sustainable chemical industry.
Challenges
We are increasingly exposed to climate-focused environmental policy and regulation 
and we must adapt to the risks and opportunities that these pose. An example 
istheKigaliAmendmenttotheMontrealProtocol,bringinghydrofluorocarbon
(HFC) gases, which have high global warming potential (GWP), under a long-term 
phase-down. Our pressurised metered-dose inhalers (pMDIs) rely on these  
fluorinatedgases(F-Gases)asapropellantandthiscurrentregulationcould
put future revenue at risk if the alternatives we are actively researching are not 
successful or cannot be substituted into the product. We are also exposed to the 
US and EU F-Gas review, when there is the risk that some F-Gases used in 
pMDI-based respiratory products could be subject to emission restrictions from 
which they are currently exempt. Loss of the medicinal exemption, or failure to have 
a long-term phased transition, could prevent or limit availability of products in our 
inhaled medicines portfolio, should these restrictions become applicable before 
the transition to our next-generation low GWP pMDIs. See the TCFD disclosure 
statement in the Annual Report for more information.
Our product value chains have been linear in nature and use raw materials derived 
from fossil fuels. We have work to do to understand how to transition to a circular 
model and more sustainable sources. 
The sustainability 
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Why it matters
Greenhouse gases (GHGs) from 
human activity are the major 
cause of the current climate crisis. 
This crisis disproportionately 
impacts the health of marginalised 
populations. By undermining the 
social and environmental drivers 
of good health, climate change has 
the potential to exacerbate and 
intensify existing social inequities 
such as poverty, forced migration, 
mental health issues and 
disparities in education, housing 
and wealth with the impacts 
eventually felt by all populations.   
The good news is that solutions to climate 
changehavedirectandindirecthealthbenefits,
representing great opportunities to improve global 
health — from nature-based solutions to diet 
changes.1 Addressing this issue is a business 
imperative, as climate change is projected to 
have detrimental impacts on workforce health, 
productivity and, if not proactively addressed, 
could compromise business resilience.2 
The time to act on climate change is now.  
 Description
Company operations, such as manufacturing 
and transportation, emit GHGs including 
carbon dioxide (CO2), methane (CH4) and 
hydrofluorocarbons(HFCs),contributingtoclimate
change. Emissions from product use are discussed 
in Product environmental stewardship, and we 
account for this emissions source alongside our 
entire value chain GHG footprint.
 Approach
•  Ambitious targets to mitigate our direct 
impacts and inspire wider system change
•  Gaining transparency on Scope 3, our greatest 
source of emissions
•  Enterprise-wide governance and 
executive-level ownership
In 2020, we launched Ambition Zero Carbon, 
committingtobecomezerocarbonby2025across
ouroperations(sitesandfleet)withoutcarbon
credits, and carbon negative in our value chain by 
2030. Our GHG targets exceed the Science Based 
Targets initiative (SBTi) reductions required to keep 
warming to 1.5 degrees Celsius, the most ambitious 
goal of the Paris Agreement. For Scope 1 and 2, 
the SBTi would have us at a 42% reduction by 
2025. In 2020, we achieved a 60% reduction 
in Scope 1 and 2 and are on track to achieve 
a 100% reduction by 2025. A cross-functional 
Governance Group was launched to execute our 
climate strategy. This committee is comprised of 
our CEO, CFO, the EVP, Sustainability and Chief 
ComplianceOfficer,andtheEVP,Operations
and IT. This group demonstrates executive level 
accountability for delivering Ambition Zero Carbon.
There is a clear link between energy consumption 
and GHG emissions. We manage both in 
consideration of the other. We use the World 
Resources Institute GHG Protocol guidance for 
Scopes 1, 2, and 3 to identify and measure our 
emissions and we use the Institute of Environmental 
Management and Assessment (IEMA) GHG 
hierarchy approach3 to prioritise our actions. We are 
working to gain transparency on our greatest source 
of emissions, Scope 3, which are emissions from 
our value chain. We are committed to using our 
influenceandknowledgetomobiliseourextensive
global supply chain to reduce their GHG emissions. 
See more in Responsible supply chain. 
We also seek ways to increase our climate 
resilience. Our approach to manage the physical 
and transitional risks and opportunities presented 
by climate change aims to align with the TCFD 
framework. See the TCFD disclosure statement 
in the Annual Report for more information. 
 Key targets and progress
Greenhouse gas reduction
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to these 
Sustainable Development Goals:
SDG 12 | Responsible consumption and production 
SDG 13 | Climate action 
SDG 17 | Partnership for the goals
42% reduction in 
Scope 1 and 2 by 2025 
— SBTi guidance 
60% reduction in 2020 
— AstraZeneca achieved 
100% reduction by 2025 
— AstraZeneca on track 
to achieve
2025 target





60% reduction in 
emissions since 2015. 
Increased procurement 
of renewable imported 
electricity was the primary 




Scope 3 emissions by 




• 29% reduction in 
freight and logistics 
emissions since 2015




tier API formulation 









89% of all electricity 




the Science Based 
Targets initiative 
(SBTi).
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Ambition Zero Carbon
Our journey 
to a carbon 
negative future
To become carbon 
negative across the 
entire value chain by 
2030 we will: 
transition to next-generation 
respiratory inhalers with 
near zero climate impact
explore how to ‘design in’ 
carbon neutrality across 
our organisation
engage with our suppliers 
to reduce emissions in 
line with the science of 
climate change
plant 50 million trees as a 
nature-based solution to 
address climate change
2030
To eliminate our 
carbon emissions 
from our operations 
by 2025 we will:
double energy 
productivity
use 100% renewable 
energy for electricity 
and heat
switch to a fully 
electric vehicle fleet
eliminate F-Gas 
emissions at our sites
2025
 
Our Ambition Zero Carbon strategy is to take climate action now for healthy people and a healthy 
planet. We will do this by becoming zero carbon in our operations (sites and fleet) by 2025 and carbon 
negative across our entire value chain by 2030. The $1 billion programme includes the launch of 
next-generation respiratory inhalers, transitioning to 100% electric vehicles and 100% renewable 
energy for heat and electricity, and a wide range of efficiency and clean energy initiatives to reduce 
climate impact to zero, in addition to a 50 million tree planting and stewardship plan.
Other includes: GHG protocol classification emissions for categories 2, 3, 4, 5, 8, 10, 13 — Capital goods, Fuel and energy-related, 




footprint3% 97%Scope 1 and 2 are approximately 
3% of our corporate footprint
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oods and services 
(pMDI patient use)


















    See Sustainability Data Summary 
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Greenhouse gas reduction continued
Sustainability in action




In 2020, 89% of our electricity use was from 
renewablesources,significantlyaccelerating
progress against our 2025 RE100 commitment. 
This was achieved through increasing renewable 
imported electricity to 99.9%4 and utilising 
5.3GWh of on-site solar PV. The remaining 
11% of power use was delivered by on-site 
combined heat and power (CHP) systems that 
use fossil gas. Decarbonising this source of 
electricity requires renewable fuels and these are 
under assessment as part of our emerging clean 
heat strategy.
As part of this strategy, we are investigating 
solutions for our global heat demand, delivered 
mostly through on-site combustion of fossil 
gas in boilers or CHP plants. In 2020, we joined 
the Renewable Thermal Collaborative, the 
leading coalition for organisations committed 
to decarbonising the energy required for heat 
in buildings and industrial processes. 
In addition, we strengthened our commitments 
under the Climate Group's EP100 and EV100 
initiatives: committing to double energy productivity 
and switch to 100% electric vehicles by 2025.
Mapping priority sites and countries
We prioritised creation of Ambition Zero Carbon 
roadmaps for our 10 key sites, which cover 
roughly 50% of our total Scope 1 and 2 emissions. 
Based on these outcomes, we have clean heat 
studies underway for our UK and US portfolios 
considering a broad range of solutions from green 
gastoelectrificationofheat.Inaddition,anelectric
vehicle (EV) readiness study has been conducted 
forallmarketswherewehaveafleetpresence.
Countriesthatare'EVready'havebeenidentified.
Partnerships towards a carbon 
negative value chain
Our Ambition Zero Carbon goals are ambitious, 
butmitigationeffortswillfailunlesswepartner
with others to transform the global economy. 
In 2020, 4% of total procurement spend was 
with companies that have set, or committed to 
set, Science Based Targets (i.e. emissions goals 
aligned to the Paris Agreement).
Challenges
AstraZeneca has integrated climate risks into 
the overall risk management process. We 
recognised climate change as a standalone 
risk in 2020, having been included as a 
sub-risk within a broader Health, Safety and 
Environment risk previously. See the TCFD 
disclosure statement in the Annual Report 
for more information.
" Congratulations to AstraZeneca on rapidly transitioning to renewable electricity 
and for committing to renewable heat. Climate Week NYC is the time and place 
where the world gathers to showcase amazing climate action and discuss how to do 
more. AstraZeneca is leading the way and showing what is possible — influencing 
companies all over the world to follow in its footsteps."
—  Helen Clarkson, CEO, The Climate Group
 Highlights
Recognition
We were ranked on the CDP Climate Change A list
forthefifthconsecutiveyear.
Using our voice to influence
To make Ambition Zero Carbon a reality, we are 
usingourvoicetoinfluencetheconversation
and encourage action. An example is our Gold 
sponsorship of Climate Week NYC 2020. During 
the opening ceremony of Climate Week, our CEO 
signed AstraZeneca onto the Race for Zero.
Reforestation is a nature-based solution 
to climate change
Launched in 2020, AZ Forest is a global initiative 
to plant 50 million trees worldwide by 2025. Trees 
naturally remove CO2 and are essential to mitigate 
theeffectsofclimatechange.Reforestationalso
helps support disease prevention through cleaner air 
for communities and supports wellbeing with green 
space for public use. More than 337,000 trees have 
been planted in Indonesia and Australia. 
We committed to 
double energy 
productivity and switch 
to 100% electric 
vehicles by 2025.
Sustainability overview Access to healthcare Environmental protection Ethics and transparency Notices 37
AstraZeneca Sustainability Report 2020
Why it matters
We recognise the link between 
a healthy planet and healthy 
people, and are committed to 
the health and safety of both. 
We must understand and 
manage pharmaceuticals in the 
environment (PIE) to ensure that 
our medicines cause no negative 
impacts on the environment.     
Trace amounts of pharmaceuticals have been 
detected in the environment for more than 20 years. 
Inmostcasesthisdoesnotcauseaproblem;
however, the presence of some pharmaceutical 
residues in the environment have been implicated 
ineffectsonwildlife.Wemustdeterminethe
risks associated with PIE to ensure the safety 
of our products throughout their life cycle. If 
we do not proactively manage these risks, our 
medicines could pollute the environment. In 
addition to environmental damage, this could incur 
reputationaldamageandfinancialliabilities.An
increased regulatory focus on pharmaceuticals in 
the environment also has the potential to restrict 
future patient access to medicines.
 Description
Patient excretion, improper disposal of unused 
medicines and discharges from drug production 
result in the release of active pharmaceutical 
ingredients (APIs) into the environment. Potential 
impactsincludeeffectsonwildlifeandhuman
health from low-level and/or long-term exposure.
 Approach
•  Environmental risk assessments 
conducted as part of marketing applications 
for new medicines
• Targets for safe discharge of pharmaceuticals 
•  Continual monitoring of environmental data 
on our medicines
•  Ongoing research to increase our 
understanding of potential impacts
We lead our industry in the management of 
PIE-relatedtopics.Wewerethefirstcompanyto
publish targets describing safe discharge limits 
for drug production and formulation facilities 
thatwereexternallyverified.Wewerealsothe
firstcompanytopublishenvironmentalrisk
assessment (ERA) data on our website and we are 
the only company with a published approach to 
ecopharmacovigilance (EPV). EPV ensures that we 
review emerging information that might change the 
way we assess and manage the environmental risks 
of our medicines. Learn more in our EPV video.
In many cases, our APIs are not detected in 
the environment. When our APIs have been 
detected, in almost all cases these APIs pose low 
orinsignificantenvironmentalrisk.Therecanbe
somelocation-specificenvironmentalrisksfor
particular pharmaceuticals, especially in regions 
where there may be inadequate sewage treatment 
and high populations of people discharging waste 
into rivers with low dilution conditions. Our ongoing 
EPV monitors whether increases in the global 
population, an ageing population demographic, 
increased access to medicines in low- and middle-
income countries, urbanisation and/or changes in 
disease epidemiology will change these risks in 
the future.
AstraZeneca works in partnership with academic 
thought leaders to develop new tools and 
knowledge to help understand the environmental 
risk that pharmaceuticals pose. We are also 
committed to supporting the next generation of 
environmental scientists. In 2020, we co-sponsored 
seven PhD students in collaboration with United 
Kingdom Research Innovation, who are conducting 
research on critical issues that underpin the 
protection of our natural environment.  
Our long-term PIE target and annual KPIs 
contribute primarily to SDG 12 — Responsible 
consumption and production, and additionally 
to SDG 6 — Clean water and sanitation.
 Learn more in Product environmental stewardship 
and Environment's impact on health.
  For more information see our 
PIE Position Statement.
 Key target and progress
Pharmaceuticals in the environment 
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes primarily to these 
Sustainable Development Goals:
SDG 12 | Responsible consumption and production 
SDG 17 | Partnership for the goals
2025 target



















publications on PIE, 
including an article on 
understanding the risk 
of pharmaceuticals in 
developing countries
• EPV programme 
to monitor product 
risks post-launch 
ran through 2020 
withnosignificant
risksidentified
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Pharmaceuticals in the environment continued
Assessing environmental risks earlier 
in drug development
The Innovative Medicines Initiative (IMI) is a 
public-private partnership that works to improve 
health by speeding up the development of, and 
patient access to, innovative medicines. The 
IMI PREMIER (Prioritisation and Risk Evaluation 
of Medicines in the EnviRonment) project, 
launched in 2020, provides an opportunity to build 
partnerships with those who want to ensure the 
environmental safety of innovative medicines. It is 
led by AstraZeneca and Radboud University and 
includes pharmaceutical companies (Bayer, BMS, 
Eli Lilly and Company, GSK, MSD, Novartis, Roche, 
SanofiandServier),theEuropeanMedicines
Agency, research institutes (Dutch National Institute 
for Public Health and the Environment, University 
of Exeter, EAWAG, Fraunhofer Institute, University 
of Gothenburg, University of Helsinki, Leuphana 
University, Mario Negri Institute and the University 
of York) and Small Medium Enterprises 
(Ecologic, ECT, Simomics and TEAM IT).
PREMIER aims to deliver an innovative framework 
for characterising the environmental risks of active 
pharmaceutical ingredients (APIs), which can be 
used to:
Develop tools and models to identify 
potentialenvironmentalhazardsand
risks associated with APIs earlier in 
drug development
Screen and prioritise legacy APIs 
authorised for use prior to 2006 for a 
tailored environmental assessment
Support the development of 
pharmaceuticals that are less 
harmful for the environment and 
promote greener manufacturing
Make environmental data on APIs more 
visible and accessible to all stakeholders
Learn more about the PREMIER project on 
our website. 
Advocating for science-based policy 
at the Society of Environmental 
Toxicology and Chemistry (SETAC) 
Many conferences moved to a virtual platform 
in 2020, a model that we hope will continue 
into the future, in order to reduce travel-related 
environmental impacts and increase the 
accessibility of science more globally.
At the virtual SETAC Europe meeting, AstraZeneca 
was a strong advocate for science-based policy. 
The discussion focused around the European 
Medicines Agency developing revised guidelines 
for assessing the environmental risk of human 
medicinal products. We co-chaired a session with 
representatives from government and academia 
investigating ways to improve the incorporation 
of academic research into such assessments. 
We advocated for a new approach to regulatory 
environmentaltoxicologytestingofAPIs;we
proposed that testing protocols for such APIs 
should be shared in a registered report to: 
(i)increasetransparency;(ii)allowinterestedparties
tocomment;and(iii)helpavoidduplicationof
regulatory animal testing. 
We also presented our research on improving 
environmental protection conveyed in regulatory 
assessments: 
• Review of the environmental risks of more than 
120 APIs to groundwater2 
• Recommendation, in collaboration with the wider 
pharmaceutical industry, for use of an exposure 
trigger for terrestrial environment assessments3
• Proposedalterationsofthetriggerforfish





The continued presence of drug residues in a 
range of drinking, surface and ground waters 
as well as soils and sediments is causing 
concern for the industry. There are increasing 
regulatory pressures including proposals from 
the European Parliament and the Organisation 
for Economic Co-operation and Development 
(OECD)toincludeenvironmentalhazardand
risk within the approval of new medicinal 
products. Future product approvals could 
beconsideredbasedonsafety,efficacyand
environmental risk. Addressing the risks now 
can improve access to medicines for patients 
in the future.
PREMIER 
aims to deliver an 
innovative framework 
for characterising the 
environmental risks of 
active pharmaceutical 
ingredients.
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Why it matters
Access to water is a fundamental 
human right.1 Water not only 
regulates our bodily functions, 
making it essential to human 
health, it also maintains the 
ecosystems that provide the food 
and other essential goods and 
services from which we benefit.2 
At AstraZeneca, water is needed 
to develop and manufacture our 
products, so it makes business 
sense for us to manage this 
resource responsibly.
Demand for fresh water is growing rapidly.3 In many 
areas around the world, water demand exceeds 
supply, and areas traditionally regarded as 
water-secure face seasonal shortfalls in meeting the 
needs of communities, ecosystems and industry.4 
Around four billion people experience severe water 
scarcity at least one month of the year.5 The World 
Economic Forum cites water crises as one of the 
greatest risks society faces over the next 10 years.6
 Description
Company operations can have adverse impacts 
on water. In water scarce regions, water quality 
and availability risks may be more pronounced 
for local stakeholders and company operations. 
This also includes the responsible discharge of 
active pharmaceutical ingredients (APIs) from 
drug production to aquatic ecosystems. 
We address water impacts from the 
production and patient use of our products in 
Pharmaceuticals in the environment (PIE).  
 Approach
• Minimise our impact 
•  Positively contribute to water stewardship 
where we operate
•  Uncouple water demand from business growth
We have initiatives across our operations to reduce 
our impact and be a positive actor in the river 
basins where we operate:
• At AstraZeneca sites: Uncoupling water 




• In drug development: Adopting process mass 
intensity (PMI) targets to reduce the water 
demandofthedrugswedevelop;conducting
life cycle assessments (LCAs) to calculate the 
water footprint across the whole product life 
cycle including the raw materials used to make 
the drug substance. See more in 
Product environmental stewardship
• Maintaining water quality: Preventing pollution 
by applying safe discharge limits for APIs 
produced or formulated by our manufacturing 
operations. See more in PIE
• In our supply chain: Applying safe discharge 
limits across our supply chain to prevent 
pollutionfromourAPIsuppliers;implementing
a Sustainability Partner Guide and Framework
• In the communities where we operate: 
Supportingriverbasin-levelcollectiveaction;
developing context-based water targets
To enable us to take a more holistic approach to 
managing our water risks across our site network, 
we have updated our methodology to include water 
scarcity. Based on the WWF Water Risk Filter tool, 
whichidentifiesandevaluateswaterrisksaround
the world, this methodology has enabled us to 
broaden our understanding of our water-related 
risks and identify areas for investment. We prioritise 
implementingwaterefficiencyprojectsandwater
efficiencyauditsinwaterscarceareas.Seeour
water scarcity map for more information.
Our longer-term ambition is to implement 
Science-Based Targets for Water, once a global 
methodology is available. With these targets, we 
aim to set a high bar on water stewardship for the 
pharmaceutical industry. This approach aims to 
ensure that we can more meaningfully contribute 
to the sustainable management of water resources 
within river basins. 
Water stewardship Our work contributes primarily to these Sustainable Development Goals:
SDG 12 | Responsible consumption and production 
SDG 17 | Partnership for the goals
    See Sustainability Data Summary 
for full metrics and methodology.
2025 target
Maintain absolute 





Water footprint was 
3.44 million m3, down 
from 3.51 million in 
2019, a 20% reduction 
from 2015. 
 Key target and progress
$4.3 return 
for every dollar 
invested 
in water and sanitation, in the 
form of reduced health care 
costs for individuals and 
society around the world.7
Managingwater-relatedrisks,suchasfloodsand
drought, is a key part of our approach to managing 
the physical climate risks we face. See the TCFD 
disclosure statement in the Annual Report for 
more information. 
Our long-term water target and annual KPIs 
contribute primarily to SDG 12 — Responsible 
consumption and production, and additionally 
to SDG 6 — Clean water and sanitation.
  For more information on our approach see 
our Water stewardship position paper. 
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Water stewardship continued
Sustainability in action
New collaboration with the 
World Wide Fund for Nature 
(WWF) Sweden
We have a shared commitment with the WWF 
towards taking better care of the natural 
environment. Freshwater is essential for biodiversity, 
which along with clean and plentiful water, is 
fundamental to AstraZeneca's mission to deliver 
life-changing medicines. 
Our twelve-month partnership with WWF focused 
on identifying opportunities to: 
Improve our water stewardship approach 
and strategy
Engage in on-the-ground water projects in 
the river basins where AstraZeneca operates 
The results of this partnership should help us to 
mitigatetherisksspecifictooursiteoperations
and strengthen our local contribution to water 
stewardship in the river basins where we operate. 
Read more on our website.
Broadening scope of water risks
In 2020 we transitioned to using WWF’s 
Water Risk Filter to complete site water risk 
assessments. We are leveraging this tool to develop 
a strategy which broadens the range of water risks 
weconsider,toincludephysicalriskslikeflooding,
access to water and sanitation, and reputational 
and regulatory risks. Including these parameters 
alongside our most material water risks — water 
quality (see Pharmaceuticals in the environment) 
and water scarcity — enables a more holistic 
approach. In 2020 we conducted a high-level 
screening of basin-level water risks across 
250 AstraZeneca sites, which included logistics and 
ITcentres.Atrisksitesweredefinedbycombining
this screening with data on the criticality of our 
sites delivering medicines to patients. A detailed 
operational water risk assessment was performed 
on the priority sites to help us respond to our 
water risk exposure. 
The Water Risk Filter also helps us understand how 
water risks will change under climate scenarios. 
Increased risk in areas where scarcity is already 
a concern highlights the need to improve our 
waterefficiencyatthesesitesandworkwithother
stakeholders in the river basins to improve water 




currently low scarcity sites that are likely to 
face medium scarcity by 2030
• Medium or high scarcity sites — Water scarcity 
is expected to become more acute at all sites 
currently located in areas of medium or high 
scarcity, comprising 15% of our site network 
that uses over 10,000m3  of water per year
 Highlights
Recognition
We were ranked on the CDP Water Security A list 
forthefifthconsecutiveyear.
Water stewardship position paper 
In 2020 we published a position paper which details 
our approach and actions.
Challenges
Pharmaceutical production requires water 
of high quality for product manufacture and 
equipment cleaning. Water scarcity has the 
potential to cause temporary site shut-downs 
in our site network or supply chain and delay 
manufacturing. Climate change projections 
indicate that these risks will grow in the coming 
years. In 2020, we conducted a screening study 
of two future climatic scenarios to explore our 
physicalclimaterelatedrisks(floods,water
scarcity,extremeheat,cyclonesandwildfires)
across 61 business critical sites. Eight sites 
were predicted to be exposed to increased risk 
ofsevereorverysevereclimate-relatedhazards
in the next 10 years based on the worst-case 
scenario. See the AstraZeneca TCFD disclosure 
statement within our Annual Report for 
more details. 
CDP A list 
We are one of only three 
companies worldwide to 
have been on the Water 
Security A list for five 
consecutive years.
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Weprioritiseimplementingwaterefficiency
projectsandwaterefficiencyauditsinwater
scarce areas. This map shows the water scarcity 
rating for AstraZeneca sites that use over 
10,000m3 of water per year.
In 2020, AstraZeneca transitioned to using 
WWF’s Water Risk Filter to complete regular site 
water risk assessments, which resulted in an 
update to the ratings. 
Sites
1  6th of October City, Egypt
2  Yelahanka Bangalore, India 
3  Coppell, United States
4  Shanghai Zhangjiang, China
5  Boston, United States 
6  Cambridge, United Kingdom 
7  Canóvanas, Puerto Rico
8  Cotia-SãoPaulo,Brazil
9  Dunkirk, France
10  Frederick, United States 
11  Gaithersburg, United States 
12  Gothenburg, Sweden 
13  Liverpool, United Kingdom
14  Louisville, United States
15  Macclesfield,UnitedKingdom
16  Maihara, Japan 
17  Mount Vernon, United States 
18  Newark, United States 
19  Nijmegen, Netherlands 
20  North Ryde, Australia
21  Philadelphia, United States 
22  Södertälje, Sweden 
23  Taizhou,China
24  Vorsino, Russia 
25  West Chester, United States 
26  Wilmington, United States 
27  Wuxi, China 




optimised to reduce the volume 
of water rejected from the units 
when preparing for manufacturing. 
Optimisations reduced reject 
flowvolumesby30%without
any impact on the quality of 
purifiedwater.Thesechangesare
expected to reduce the site's water 
footprint by 20% or 34,000m3 a 
year. This represents a saving of 
$50,000 in costs annually.
West Chester, United States Newark, United States
Optimising steam condensate
Upgraded chiller condenser pumps 
and the installation of metering will 
help optimise our steam condensate 
water consumption. These changes 
are expected to reduce the site's 
water footprint by 3% or 2,250m3 
a year. 
Improving operational water efficiency




manufacturing processes, and a stream which is 
rejected.OurteamatTaizhouidentifiedthatalthoughthe
rejected water had too many impurities to be used in our 
manufacturing processes, it could be reused elsewhere 
onthesite.Afterinstallingequipmenttocollectandfilter
rejected water, it can now be reused in cooling towers. 
This has resulted in reducing the site's water footprint 
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Why it matters
Waste is accumulating across 
the world at a rate faster than the 
Earth is able to digest or humans 
are able to process. Waste is the 
result of a linear use of resources 
— take, make, waste — and has 
the potential to pollute. This can 
lead to negative impacts on the 
health of the planet and people.    
Inappropriately disposed waste can cause 
respiratory diseases and other adverse health 
effects,ascontaminantsareabsorbedfrom
lungs into other parts of the body.1 Waste can 
also contaminate surface water and marine 
environments, leading to negative impacts for 
humans and ecosystems. Reduction of waste 
makes business sense because it increases 
efficiency,savesusmoneyandreduces
human and environmental risks. 
 Description
Company operations generate waste, including 
biologicalwasteandhazardouswaste,andwe
work with specialist third parties to manage its 
disposal. Waste can have adverse impacts on the 
environment and human health through pollution.
 Approach
We look at waste not only in its end state, but 
also evaluate how it was produced. We promote 
a waste hierarchy, focusing on waste prevention 
and reduction, then prioritising the reuse, recycling, 
repurposing and safe disposal of the waste 
materials we produce in distinct ways: 
In production: We look for product design 
(see process mass intensity — PMI) and process 
innovations to decrease waste by-products 
created during manufacturing. We use solvent 
recovery systems to reduce the need for 
raw materials
On-site with employees: Employees identify 
waste elimination projects and implement 
process changes or apply for funding from the 
Natural Resources Reduction Governance Group 
(NRRGG)
For disposal: We maximise opportunities to 
reuse and recycle where possible
We are also exploring circular business models to 
maximiseresourceefficiencytoaratetheEarth
can regenerate and help the global community 
stay inside the planetary boundaries. 
We follow these circular economy principles:
• Design out waste and pollution: designing 
out the negative impacts of economic activity 
that cause damage to human health and natural 
systems, including the release of greenhouse 
gasesandhazardoussubstances,pollutionofair,
land, and water, as well as structural waste 
• Keep products and materials in use: favouring 
activities that preserve value in the form of 
energy, labour, and materials. This means 
designing for durability, reuse, remanufacturing, 
and recycling to keep products, components, 
and materials circulating in the economy
• Regenerate natural systems: avoiding 
non-renewable resources and preserving 
or enhancing renewable ones. For example, 
we know that to achieve our carbon 
negative value chain target by 2030 it may be 
necessary to gradually transition from fossil 
fuels to biological sources for solvents and 
plastics where possible. We are considering 
any unintended consequences of this 
transition, for example there is a risk that 
producing bioplastics could drive changes 
in land use, water use and nitrogen and 
phosphorous demand
In 2020, AstraZeneca became a founding 
member of the Circular Bioeconomy Alliance and 
co-authored the 10-point action plan for the circular 
bioeconomy. In parallel, we developed a roadmap 
to integrate circularity across our business. To 
support this process, we ran a virtual ideation event 
to source ideas on how we can apply a circular 
mindset across our value chain. The output was a 
prioritised list of actions for implementation across 
medicine development, product manufacture, 
devices, packaging, logistics, facilities and built 
assets and procurement. 
 Key targets and progress
Waste management
2025 target
Reduce waste by 10% 




Total waste was 
30,262 tonnes, down 
11% from 34,173 tonnes 
in 2019, representing 
a decrease of 2% 
from 2015.
2025 target
All of our R&D sites with 




Six of our R&D sites 
werecertifiedby 
My Green Lab.
Our work contributes to these 
Sustainable Development Goals:
SDG 12 | Responsible consumption and production 
SDG 17 | Partnership for the goals
    See Sustainability Data Summary 
for full metrics and methodology.
We realise that to be 
successful in the long term, 
we must embrace movements 
like the circular economy to 
balance our environmental 
footprint to what the Earth 
can sustainably reproduce 
and regenerate. 
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Eliminating plastics from packaging
We are eliminating 70 million single-use plastic 
(SUP) items per year from a respiratory therapy 
device by removing a plastic packaging sleeve. 
This plastic sleeve served regulatory requirements 
to ensure a user was aware the device had not 
been tampered with. In response to new regulatory 
guidance stating that if device packaging has a 
tamper evident label (TEL) a sleeve is no longer 
required, we removed this layer of packaging from 
production in a range of markets, including the 
EU, US, and China.
Patients are being assured with communication 
about the sleeve removal and targeted training for 
healthcare professionals interacting with patients 
who are prescribed this treatment. 
Waste management continued
Sustainability in action
From plastic waste to by-product
OurOperationsteaminSwedenidentifiedan
opportunity to turn what was previously viewed 
as waste into a useful by-product. We use 
polyethylene plastic to make packaging for one 
of our respiratory therapy products, but the 
manufacturing process generates a high proportion 
of residual plastic. Previously this material was 
categorised as a waste to be recycled, but in 
2020 the team successfully demonstrated to the 
regulatory authorities that the residual plastic 
meets the standards required to be classed as 
a by-product that can be directly used as a raw 
material. Following shredding on our site, over 
1,000 tonnes of plastic a year will now be sold as 
a high-quality raw material to produce new plastic 
goods, reducing the need for the production of 
virgin plastics.
Tackling process waste 
The production process at our Coppell site in 
Texas, US, generates a large volume of high silica 
waste with a high water content. This waste stream 
is currently relatively small, but is expected to grow 
significantly.Thesiteteaminitiatedaprojectto
installtwofilterpresserstoneutralisethewaste
stream and separate high silica from the treated 
water. This separation and treatment process will 
enable us to send the treated wastewater to the 
localtreatmentplantforfurtherpurification.These
changeswillcutwastesenttolandfillbymorethan
70%, reducing transportation costs, and diverting 
upto5,000tonnesperyearfromlandfill.Theteam
is looking for opportunities to recycle the residual 
wastetoeliminatetheneedfordisposaltolandfill.
Improved productivity: 
Up to 2.5 million
additional products per year can 
be manufactured by removing 




of single use plastic (SUP), 
equivalent to 20 tonnes of 
plastic eliminated per year
Read more about what we’re doing to address 
the environmental footprint of our products in 
Product environmental stewardship. 
Expected results:
Unused plastic is now classed as a high quality raw material to 
manufacture new products.
Over 1,000 tonnes 
of plastic a year will now be sold 
as a high-quality raw material 
to produce new plastic goods, 
reducing the need for the 
production of virgin plastics.
We are eliminating 
70 million single-use 
plastic items 
per year from a respiratory 
therapy device by removing a 
plastic packaging sleeve. 
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Addressing our environmental 
footprint in the labs
We want to innovate for patients in sustainable 
ways, and our activities in the lab, from washing 
glassware to disposing of gloves, all have an 
environmental impact. This is the second year we 
haveworkedwiththenot-for-profitorganisation, 
My Green Lab. Through our Green Lab programme 
andMyGreenLabcertificationprocess,
AstraZeneca scientists learn how to improve our 
lab practices with respect to waste, energy, water 
and chemicals. This programme brings to light 
environmental impacts that were perhaps invisible 
before, as well as providing a space for scientists 
to make their own sustainability ideas a reality. 
Examples of energy and waste saving 
activities in 2020 include: 
Installing timer plugs for laboratory 
equipmenttoshutequipmentoff
after hours 
Switching to electronic pipette 
calibration records across the 
Cambridge sites, which will save 
6,400 sheets of paper each year
The South San Francisco site diverted 
240 kg of uncontaminated gloves from 
landfill,recycled240kgoftipboxesand
39 kg of laboratory safety glasses
Our 2020 Green Lab programme progress: 
Waste management continued
Sustainability in action Challenges
As our production levels are projected 
to grow in the future, achieving our total 
10% waste reduction target will be a challenge. 
We have contracted external expertise to 
support with a waste opportunity assessment 
programme to help us decouple business 
growth from waste generation. We also face 
many barriers to realising circularity. There are 
very tight regulations for plastics and materials 
in contact with drug substance or for wastes that 
have residual active pharmaceutical ingredients.
 Highlight
Reducing single use plastics in our offices
In 2020 AstraZeneca signed the UK National Health 
Service (NHS) Plastics Pledge across all our major 
sites. We set a target to remove 4 million plastic 
itemsfromourofficesandfoodservices.Whilewe
reduced over 3.5 million items, the pandemic led to 
a delay in completing some planned initiatives, such 
as the removal of single use milk servings. This was 
inanefforttoreducecommontouch-pointsto
protect the health of our workforce that was on site, 
and who continued to deliver medicines to patients 
throughout the pandemic. 
SUP pledges:
End purchase of SUP stirrers and straws 
by April 2020 — achieved
End purchase of SUP cutlery and plates, 
and certain cups by April 2021 
— in progress
Reduce SUP food containers and other 












Won the Top Organisation Award for the 2020 
Freezer Challenge in the biotech/biopharma category. 
Through activities like freezer clean outs, maintenance, 
temperature setbacks from -80°C to -70°C, and 
upgrades to more energy-efficient models, eight sites 
saved a combined 1.1 million kWh/year, equivalent 
to emissions from 90 homes' energy use for one year. 
Read more in Nature
6
of our R&D 
sites certified gold 
level or higher by 
My Green Lab, 
meaning that each 
site has implemented 






•  3 Operations sites
•  6 R&D sites 
Scientist at our South 
San Francisco site 
adjusting freezer set point 
in the lab to -70°C. 
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has a ‘Speak Up’ 
culture
89%
of employee survey 
respondents feel 
that AstraZeneca 











with the Code 





Contributing to the 
Sustainable Development Goals, 
a universal blueprint for prosperity 
for people and the planet, now and 
into the future.
SDG 3 | Good health and wellbeing
SDG 5 | Gender equality
SDG 8 | Decent work and economic growth
SDG 17 | Partnership for the goals
Equality and prosperity for all 
fosters healthy societies
Connection to health:
Fostering a culture of doing 
the right thing across our 
value chain promotes health 
and wellbeing
Our ambition:
Create positive societal 
impact and promote 
ethical behaviour in 
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We believe that people, the planet 
and business are interconnected. 
We want to be valued for not only 
our medicines, but also for the 
way we work. We aim to build 
trust by demonstrating integrity, 
transparency and fair treatment 
in everything that we do. We have 
committed to ensure racial equity 
in our workplace and access to 
our medicines, in our clinical 
trials and beyond. 
As a global company with more than 75,000 
employees operating in more than 100 countries, 
weworkhardtofulfilourresponsibilitiestoour
wider value chain, local communities and our 
own people. 
The big picture
Organisations are no longer valued or trusted 
solely on the quality of products and services, and 
financialperformance.Tobetrusted,companies
need to be transparent about how their operations 
are impacted by sustainability issues and how their 
operations impact stakeholders. 
Historically, the pharmaceutical industry has faced 
challenges in building and maintaining its reputation 
and the trust of its stakeholders. This was as a 
result of improper sales and marketing practices by 
some companies, for example in pricing practices, 
as well as enquiries or investigations by government 
and regulatory authorities. The industry’s response 
to the COVID-19 pandemic and the quick 
mobilisation of resources to developing vaccines 
may help to increase the public's trust. But there 
remains much work to be done. 
Our approach to 
Ethics and transparency
Our shared Values underpin all our activities and 
serve as a compass to guide us in our interactions.
We follow the science
Weputpatientsfirst
We play to win
We do the right thing
We are entrepreneurial
The behaviours that describe our Values were 
updated in 2020 to explicitly highlight the 
importance of inclusion and diversity across 
our company and in the patient populations we 
support. See Inclusion and diversity for more. 
Our approach goes beyond rules and policies to 
impact behaviour: we empower our workforce to 
use their judgement to do the right thing. We have 
established policies that guide our workforce on 
how to apply values-based decision making in 
theirday-to-daywork—fromscientificresearch
in the laboratory to interactions with colleagues, 
healthcare professionals, patients and supply 
chain partners. 
Governance
Ethics and transparency spans many areas of 
workforce culture and performance. While every 
member of the workforce contributes to the delivery 
of our material focus areas, we govern them each 
distinctively across several business areas: Human 
Resources, Operations, Legal, R&D and Global 
Sustainability. There is often overlap in the scope 
of focus areas, so we work to collaborate across 
functions to manage strategy and outcomes. 
Ourunifiedquarterlyscorecardtracksmore
than 10 Ethics and transparency metrics and 
communicates our performance to all employees. 
Ethics and transparency overview
  Material focus areas




Talent and workforce evolution





• Ethical business culture:Publishedartificial
intelligence ethics principles and governance
• Inclusion and diversity: Committed to racial 
equity in our workplace and beyond
• Talent and workforce evolution: Launched 
new performance development approach
• Workforce wellbeing and safety: Shared 
wellbeing resources for employees 
and leaders during COVID-19
• Responsible supply chain: Launched supplier 
diversity programmes in two new countries
• Human rights:Identifiedpotentialhuman
rights impacts in our supply chain
The events of 2020 
accelerated and amplified 
existing inequities, widening 
the cracks in global economic and 
industrial systems, and underscoring 
the importance of AstraZeneca's 
commitment to address health 
disparities and promote 
health equity.  
We recognise that several of our annual 
Ethics and transparency measures were 
impacted by the pandemic and may not 
reflect a typical trajectory.
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Why it matters
There is a lack of public trust in 
big corporations.1 Scepticism is 
even greater towards companies 
in the pharmaceutical industry. 
This trust deficit impacts the 
ability to attract talent and 
maintain a healthy, productive 
workforce and the partnerships 
necessary for innovation and 
bringing healthcare solutions 
to more people.  
The reputational, legal, regulatory and long-term 
sustainability risks make an ethical business 
culture imperative.
 Description
Company Values and norms, practices, standards 
and principles that guide the actions and behaviour 
of employees, including the Code of Ethics, and 
acting in an ethical manner that goes beyond 
compliance with policies and regulation. This 
applies across our company’s operations and our 
entire value chain. This issue includes bioethics 
(including animal welfare), anti-bribery and 
anti-corruption, data transparency, intellectual 
property, responsible lobbying, and responsible 
sales and marketing. 
 Approach
Our Code of Ethics serves as our moral compass. 
Additional requirements at the local and business-
unit level complement our Code. We know that 
setting rules is not enough — which is why we 
emphasise values-based decision making. We 
encourage our workforce to adopt a sustainability 
mindset that embraces our core Values. 
We strive to model an ethical business culture by 
going above and beyond compliance with legal and 
regulatory requirements. This includes fostering an 
environment where:
Employees make it safe for others to speak up
Employees feel comfortable to speak their minds 
ifthey(i)haveanideaorinnovationtoshare;(ii)
see behaviour that is not aligned with our Values
 Code of Ethics 
In today's information-seeking society, our 
actions add more value by being visible. 
Transparency supports learning and development 
for our employees, suppliers and partners. 
It also meets expectations of patients, 
investors, and broader society.
On www.astrazeneca.com/sustainability we share 
supplementary reports, stories and infographics to 
provide information in a number of formats to suit 
diverse stakeholder preferences.
 Governance 
Our Executive Vice-President (EVP) of Human 
Resources is accountable for our 'Speak Up' 
culture.OurChiefMedicalOfficer,whoreports
to our EVP of Oncology R&D, is accountable 
for Bioethics matters. Our EVP, Sustainability 
andChiefComplianceOfficerisaccountablefor
data privacy, sustainability strategy, and safety, 
health and environment matters, as well as 
reporting to the Audit Committee on bribery and 
corruption risk, safeguards and breaches. Our 
Audit Committee annually reviews our systems to 
prevent bribery and corruption. Where a breach has 
been substantiated, we take corrective action, up 
to and including termination of employment or 
third-party engagement. We also take steps to 
prevent recurrence, including enhancements 
to our controls.
  See our Global Standard on Anti-Bribery 
and Anti-Corruption. 
 Key targets and progress
Ethical business culture
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to this 
Sustainable Development Goal:
SDG 17 | Partnership for the goals
2020 target
Ensure AstraZeneca has 




• 84% of employee 
survey respondents 
feel we have a 
'Speak Up' culture, 
up from 80% in 2019
• 49.1 instances of 
non-compliance with 
the Code of Ethics per 
thousand employees in 
commercial business 
units, down from 
63.3 in 2019
• 84% of employee 
survey respondents 
feelsufficienteffort
is made to get the 
diverse opinions and 
thinking of employees, 
up from 80% in 2019




units, down from 
434 in 2019
2025 target
100% of active 





100% of active 
employees trained 
in 2020.
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Ethics and Artificial Intelligence  
Rapidadvancementsinthefieldofartificial
intelligence (AI) are revolutionising the 
pharmaceutical industry. At AstraZeneca, 
these advances have already begun to change 
the way we work. AI systems can help us:
• Better understand diseases and match patients 
with the right clinical trials by creating biological 
insight knowledge graphs
• Automate processes using robotics and improve 
oursupplychainwhendeliveringmedicines;
helping us to design clinical trials in a faster, 
smarter way that develops our medicines more 
efficientlytoservepatients’needs
• Provide customised training and support to our 
employees, to further their career development
Along with excitement and opportunity, AI systems 
bring new ethical considerations. Algorithms 
and solutions need to be developed to behave 
ethically when used for autonomous decision 
making. For example, mechanisms are needed to 
ensure algorithms — which are written by humans 
— do not replicate entrenched human biases 
related to race, gender, etc. In 2020, we engaged 
experts inside and outside AstraZeneca to develop 
principles around data and AI to address this type 
ofethicalissue.Wearethefirstpharmaceutical
company to publicly share this type of ethical 
framework for the use of AI. We will continue 
to evolve our thinking and approach as these 
areas mature. Learn more on our website.
More inclusive case 
management platform 
In 2020, AstraZeneca launched a new ethics 
case management platform.Theplatformoffers
three options — a helpline, an online form and text 
messaging (US only) — for employees and external 
stakeholders to speak up about compliance 
concerns, make a report or raise questions. 
Aspartofoureffortstobeinclusive,thenew
helpline: 
• Can be reached from our company’s website 
• Displays all the information on the same web 
page, including a new text reporting option 
(US only)
• Sets expectations with the reporting party 
regarding next steps, allowing the reporting party 
to decide if they want to be contacted for further 
information while protecting their identity 
• Is available in 58 languages, up from 38, 
and 151 countries, up from 123
Ethical business culture continued
Sustainability in action Challenges
SomeriskofineffectivelyaddressingEthical
business culture is included in — 'Failure to 
meet regulatory and ethical expectations on 
commercial practices, including anti-bribery and 
anti-corruption,andscientificexchanges'—
an AstraZeneca principal risk with the potential 
to have a material impact on our business or 
results of operations. The risk 'Failure to adhere 
to applicable laws, rules and regulation' also 
references aspects of Ethical business culture. 













 Socially Benefi cial
AstraZeneca's 
principles for 
Ethical Data and 
AI systems
Mechanisms are 
needed to ensure 
algorithms — which are 
written by humans — do not 
replicate entrenched human 
biases related to race, 
gender, etc. 
 Highlight
Engaging employees on ethics
2020markedourfirstcelebrationofGlobalEthics
Day. Designed to inspire, challenge and educate, 
the campaign's theme, Ethics in Action, provided 
an opportunity to showcase the ethical work 
underway across all our business areas. Global 
events included streamed talks on what ethics 
means at AstraZeneca, highlighting projects with 
strong innovation and ethics themes, and a live 
facilitated debate posing ethical questions at 
work. Posts from 37 countries generated over 
59,000 views on our internal social media platform. 
" The impact of our AI solutions on health and society is more complex than before, 
and AI regulations and public expectation are still developing. I am hopeful these 
principles bring confidence to our patients, partners and ourselves as we learn 
together how to apply them in practice to our work."
—  Margi Sheth, 
R&D Data Policy Director and Project Lead
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Why it matters
As a science-led company, 
we are dependent upon biological 
and medical research. For 
example, in the case of animals 
in research, some pharmaceutical 
regulations require medicines to 
be tested on animals before they 
can be considered to be safe for 
human use. We must consider 
the associated ethical issues 
that arise in both the short- and 
long-term. This careful assessment 
of our science and the impact on 
our stakeholders is essential to 
be able to deliver our life-changing 
medicines to patients now and 
in the future.  
 Description
Bioethics refers in the broadest sense to the range 
of ethical issues that arise from the study and 
practice of biological and medical science. While 
there are many discrete subject matter areas within 
thefieldofbioethics,atAstraZenecaweseethem
as an integrated whole, considering our company 
Values,includingputtingpatientsfirst,followingthe
science and doing the right thing.  
 Approach
Our Bioethics Advisory Group (BAG) brings 
together subject matter experts to oversee 
bioethical issues. The BAG maintains the accuracy 
and consistency of the Global Standard: Bioethics, 
provides subject-matter expert advice in response 
to stakeholder enquiries, and conducts 
horizon-scanningtoanticipatebioethical 
trends and issues. 
The BAG remit was expanded in 2020 to 
include decisions on exemptions to payments 
for participants in research and workforce 
matters, which demonstrates our application of 
bioethics across AstraZeneca. Our Chief Medical 
OfficerservesastheowneroftheStandardand
sponsor of the BAG. 
The BAG governance activities communicate the 
importance of bioethical concerns across the 
business, focusing on these bioethics topics:
See the interactive PDF on our website to learn 
more about the care we take to manage the ethics 




Technology has not yet advanced to the stage 
where all animal use can be fully eliminated from 
research and development. In addition, some 
animal studies are required by international 
regulators before medicines progress to human 
trials. Animal studies therefore remain a small, 
but necessary, part of the process of developing 
new medicines. Animal welfare is a top priority for 




Science and Animal Welfare (C-SAW), which is 
the enterprise-wide group overseeing all of our 
use of animals both within our own facilities and 
at third party locations where work is conducted 
on our behalf. The main functions of C-SAW are 
promoting the 3Rs widely across AstraZeneca, 
encouraging openness and transparency about 
our use of animals, and fostering initiatives to 
promote a culture of care. The C-SAW ensures our 
governance and oversight mechanisms are robust, 
and that we are continually working to improve 
laboratory animal science and welfare. 
Human biological samples (HBS)
Our HBS Governance Team oversees our collection, 
storage, use and disposal of HBS in R&D, including 
human foetal tissue (hFT) and human embryonic 
stem cells (hESC). The team also approves or 
rejects proposals for experiments using hFT and 
hESC. In the rare case that hFT or hESC are 
used,aninternalreviewofthescientificvalidity
of the research proposal will be conducted and 
permission to use the tissue will be granted only 
whennootherscientificallyreasonablealternative
is available.
In 2020, two additional new research proposals 
that include use of hFT or cells derived from 
hFT were approved, one was required to meet 
regulatory requirement. Four projects using hFT 
had progressed as at 31 December and three 
projects are ongoing. An additional three projects 
using hESC were approved in 2020, resulting in 
13projectsusing24differenthESClinesorderived
cellshavingbeenapprovedasof31December;
seven projects are ongoing. 
Ethical business culture – bioethics
    See Sustainability Data Summary 





















Rats are the second most commonly 
used species in research, after mice.
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Ethical business culture – bioethics continued
Advancing COVID-19 
efforts through HBS
The use of human biological samples (HBS), 
such as solid tissue and genomic information 
(e.g. from DNA, and/or RNA within human tissues 
and preclinical models), plays a vital role in 
developing a deeper understanding of human 
diseases and their underlying mechanisms. 
For example, HBS can be used to identify 
new biomarkers, which can predict the likely 
effectivenessofapotentialnewmedicineand
identifysomeofthepossibleunwantedeffects.
Our processes must ensure that we are doing the 
right thing and putting the donors' wishes at the 
forefront of how we manage their precious samples. 
Wealsohaveanethicalresponsibilitytoourstaff.
In2020,thatincludedofferingCOVID-19screening
to support safety in the workplace, which was 
set up following careful considerations of ethical, 
legal and logistical requirements. 
Applying bioethics to 
workforce matters
Ethical issues can arise when employees are 
provided with opportunities to participate in our 
scientificactivities.Wehaveutilisedtheexpertise
of our Bioethics Advisory Group (BAG) to ensure 
the principles that underpin our approach to 
bioethics and the content of our Global Standard, 
such as ensuring appropriate informed consent, 
protection of personal data and collection of human 
biological samples, are applied consistently to 
activities involving our employees. In 2020, the 
BAG provided guidance on:
• Testing our employees for COVID-19
• Participation of our employees in clinical trials
• Governance decisions in the exception process 
for payments to participants for involvement 
in AstraZeneca research
A retrospective of innovation in 
the care and use of animals 
Since 2014, the Council for Science and Animal 
Welfare (C-SAW) has held an annual global awards 
programme celebrating excellence in the 3Rs. 
The competition expanded over the years to 
include recognition for achievements in openness 
and transparency, and in building a culture of 
care. In 2020, in lieu of the annual awards event, 
which is planned to return in 2021, we looked 
back on the achievements of the last six years. 
Highlights include: 
The launch of our new 3Rs database. 
The resource has more than 200 
records available to promote the 
uptake of existing innovations and 
inspire new advances
Virtual events with previous winners, 
external experts, and members of the 
judging panel
Reflectionsfromcolleaguesacross
the business on how we live our Values 




continue to gather pace, meaning that 
regulations and governance need constant 
focus in order to ensure they remain relevant 
andeffective.Weencounternewethical
considerations that evolve with our growing 
pipeline and scope of operations, as illustrated 
by the COVID-19 guidance requested for 
testing employees. 
Sustainability in action
 Development of potential monoclonal antibodies
Development and validation of staff screening
Setup and sample collection for ongoing vaccine trials
HBS played a very important role in 
AstraZeneca’s efforts to support the fight 
against COVID-19 by providing rapid 
access to samples for:
See more of our efforts in COVID-19 actions.
Our processes 
must ensure that we 
are doing the right thing 
and putting the donors' 
wishes at the forefront of how 
we manage their precious 
samples. We also have an 
ethical responsibility to 
our staff. Scientists who work 
on bioethics topics.
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Why it matters
Discrimination and injustices are 
detrimental to fostering a healthy 
society, planet and business. 
As a healthcare company, we 
are committed to equity in the 
delivery of healthcare.   
By supporting equity, we are addressing 
unsustainable aspects of healthcare related to 
race, ethnicity and socioeconomic status: 
• Unequal distribution of clinical trial sites relative 
to population may impede patients’ participation 
in clinical studies and contribute to the low 
representation of minorities in certain studies1
• Socioeconomic disparities contribute to 
challengesofaffordabilityofmedicines,proximity
to healthcare providers and the privilege to take 
timeoffworkfortreatment
• The lack of workforce diversity in the 
pharmaceutical industry and healthcare
Inclusion and diversity is good for our workforce 
and our business. We know that bringing together 
differentthinkingisthefoundationofourinnovation.
The unique perspectives of our people give 
AstraZeneca a competitive advantage as we push 
the boundaries of science to deliver life-changing 
medicines to patients. Studies show that diverse 
management teams drive a 19% increase in 





of the populations in which we operate, as well as 
differentbackgrounds,culturesandexperiences.
This involves going beyond non-discrimination to 
promoting equity and inclusive behaviour in the 
workplace and communities where we operate.  
 Approach
In recent years, we have had 50% representation 
of men and women in our workforce and we are 
aiming for the same at management levels, but 
gender is only one measure of diversity. In 2020, 
we set the ambition to ensure racial equity in our 
workplace and access to our medicines, in our 
clinical trials and beyond. 
Inclusion and diversity is one of the foundations 
of our People strategy — driving innovation, 
engagement and a sense of connection 
and belonging. We have three priorities for 
Inclusion and diversity: 
• Empowering inclusive leadership: We value, 
seekoutandmakethemostofourdifferences
to achieve our company goals. We contribute to 
a psychologically safe environment and make 
decisions transparently. Inclusive leadership 
is the expected way of working for everyone, 
at every career level
• Fostering a culture where people can speak 
their mind: We speak our minds and make it 
safe for others to do so. We challenge behaviours 
that are not in line with our Values, and welcome 
and suggest alternative ideas and constructive 
feedback. We empower decision making at the 
appropriate level
• Building and sustaining a diverse leadership 
and talent pipeline: We seek to attract, retain 
anddevelopdiversetalentthatreflectsand
serves our communities and patients. We aim to 
understand our demographics and take action 
globally at each stage in the talent pipeline
We are a founding partner of the World Economic 
Forum’s Partnering for Racial Justice in Business 
initiative, a coalition of 48 organisations representing 
13 industries, with more than 5.5 million employees. 
It is focused on commitments to eradicate racism 
in the workplace and set new global standards for 
racial equity in business. It also provides a platform 
for businesses to advocate together for inclusive 
policy change. 
 Key target and progress
Inclusion and diversity
    See Sustainability Data Summary 
for full metrics and methodology.
2025 target





46.9% of women 
in senior middle 
management roles 
or higher, up from 
45.4% in 2019. 
AZPride meet and greet.
Our work contributes to these 
Sustainable Development Goals:
SDG 5 | Gender equality 
SDG 17 | Partnership for the goals
As a healthcare 
company, we have 
an obligation to play 
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 Governance 
Inclusion and diversity is a responsibility that starts at the top and spans to every level of our organisation. 
Our CEO, Pascal Soriot, chairs our Global Inclusion and Diversity Council — a diverse, strategic body of 
senior and rising leaders that develops and implements our Inclusion and diversity plans. 
Inclusion and diversity continued
Board of Directors
Conduct biannual reviews of the AstraZeneca workforce composition, covering a range of metrics, 
including diversity trends in terms of gender, ethnicity and age
Senior Executive Team (SET)
Review diversity trend metrics at least quarterly, including gender, ethnicity and age
EVP of Human Resources, a SET member who reports to the CEO
Accountable for Inclusion and diversity strategy and delivery of enterprise-wide internal 
and external targets and KPIs
Functional areas
Set and deliver function-level targets and KPIs aligned with enterprise-wide strategy
Global Inclusion and Diversity Council (Chaired by our CEO and comprised 
of senior and rising leaders from across AstraZeneca)
Custodians of AstraZeneca’s Valuesandbehaviours;approvesglobalsignatureinitiatives;
contributes to and reviews functional, site and country plans
Geographic working groups
Deliver site and country plans and global initiatives at a local level
Employee Resource Groups
Connect people across AstraZeneca and provide peer-to-peer support
All employees
Live out our Values and embrace the opportunity to become champions of Inclusion and diversity
Embedding Inclusion and diversity 
into our behaviours 
Our shared Values bind us together and guide us in all 
that we do, both in the decisions we make and the way 
we drive our company forward. We have 10 behaviours 
that provide examples of the way we should live out our 
Values. These behaviours were updated in 2020 to explicitly 
highlight the importance of Inclusion and diversity across 
our company and in the patient populations we support.
 We Put Patients First
“I strive to understand the needs of diverse patient populations 
and act accordingly.” This highlights our commitment to ensure 
that everything we do considers the diversity of the communities 
we serve — from clinical trials through to making our medicines 
available to all patient populations.
We Play to Win
“I build high performing, inclusive and diverse teams that 
collaborate across the enterprise.” This supports our 
commitmenttoseekingoutandvaluingeachother’sdifferences,
making it safe for people to be themselves and incorporating 
cultural understanding into the way we work with each other — 
all with the aim of better serving patients.
We Do the Right Thing
“I speak my mind and make it safe for others to do so." This 
reflectsourcommitmenttoencourageeveryonetocontribute
to a psychologically safe environment by demonstrating an 
open mind, active listening and transparent decision making. 
We should all feel safe to speak our minds and challenge 
behaviours that are not in line with our Values. By encouraging 
one another to speak our minds, we can unleash our collective 
potential — to continue to innovate and deliver life-changing 
medicines to patients.
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Inclusion and diversity continued
Challenges
SomeriskofineffectivelyaddressingInclusion
and diversity is included in — 'Failure to attract, 
develop, engage and retain a diverse, talented 
and capable workforce' — an AstraZeneca 
principal risk with the potential to have a 
material impact on our business or results of 
operations, as described in our Annual Report.
Sustainability in action
Walking the talk on racial equity
We recognise the urgent need for organisations to step up and put an end to systemic racism. In the wake of the social atrocities highlighted by the Black Lives 
Matter (BLM) movement and health and economic disparities faced by racial and ethnic minorities during COVID-19, our Global Inclusion and Diversity Council and 
employee-led dialogues spurred AstraZeneca to act on these issues. Colleagues across the globe shared how challenges related to health inequities, COVID-19 
and BLM, are manifesting in their functions and regions. Based on constructive ideation, we initiated new actions to support racial equity:
Talent pipeline 
• Understanding and tracking our workforce 
demographics. This action holds AstraZeneca 
accountable to ensure our workforce 
is representative of the communities in 
which we operate  
• Committing to increasing minority representation 
at career level F and above. We are setting 
internaltargetsfirstintheUSandUK,
where we have more comprehensive data, 
to ensure our workforce is representative of 
demographics in those countries. We launched 
a Brand Leadership Institute pilot in the US 
to support female leaders of colour through 
a transformational learning experience. The 
programme seeks to addresses the barriers 
to leadership and bridges the gap to create 
a competitive advantage
• Increasing promotion rates of under-represented 
demographic groups in part by ensuring diverse 
candidates and interview panels
• Investing more than $5 million in early talent 
programmes to increase minority representation 
across functional areas over time
Employee resources 
• Educating our workforce through a new 
mandatory conscious inclusion online training
• Updating and socialising an Inclusion and 
Diversity Standard to make clear our stance on 
racism, consequences of violation, and paths 
for remedy
• Power of Diversity week — We believe 
in building an inclusive culture and making the 
most of our diversity. This strength enables us 
to push the boundaries of science to deliver 
life-changing medicines to patients. To celebrate 
andshowcasethis,weheldourfirst-ever
Power of Diversity week which included a 
series of global and local activities to discuss 
the importance of inclusion and diversity, 
and understand the role all employees play in 
progressing our priorities. Topics ranged from 
systemic racism to addressing healthcare 
disparities and were customised by each 
site or region to be most applicable to local 
needs. There were interactive sessions as well 
as discussions led by senior leaders, setting 
the tone from the top and sparking honest 
conversation about inclusion and diversity. 
To continue the learning, content is accessible 
to all employees through Degreed, our online 
learning platform
External actions
Beyond the actions within our organisation, we also 
aim to be part of the solution in the world around us 
byevolvingourpracticestoreflectthediversityof
the communities we serve. Our plans include: 
• Ensuring our clinical trials represent the diversity 
of the communities with the relevant disease. 
See Responsible R&D for more information 
• Ensuring the patient advocacy groups, key 
opinion leaders and lead investigators we work 
with are as diverse as the patients we reach
• Collaborating with patients to build health equity 
for minorities, including $5 million in funding for 
a US healthcare equities programme
• Joining the Consortium on Diversity and Equity 
(CODE), led by the Center for Healthcare 




We support an inclusive and diverse supply chain 
through our supplier diversity programme. In 2020, 
we expanded our programme to South Africa and 
the United Kingdom, making the programme active 
in four countries, including the United States and 
Brazil.SeeResponsible supply chain for more.
A Gendered Approach to NCD Prevention
Gender is a key social determinant of health. That’s 
why our Young Health Programme (YHP) takes a 
gendered approach, recognising that girls and boys 
havedifferentlevelsofexposureandvulnerability
to non-communicable disease (NCD) risk factors. 
Through our programmes with Plan International, 
57% of young people reached by the YHP are girls.
Recognition
• Bloomberg Gender Equality Index — One of 380 
companies selected
• 2020 Diversity List by Diversity Inc — One of 50 
companies selected
• Corporate Equality Index — Earned 100% on the 
Human Rights Campaign's index, designating 
AstraZeneca one of the 'Best Places to Work for 
LGBTQ Equality'
• MexicoEquitycertification from the Human Rights 
Campaign Foundation, which recognises top 
Mexican LGBTQ+ employers
• Workforce Disclosure Initiative — AstraZeneca 
disclosed information on key workforce-related 
topics including pay, contract types and diversity
Employees participate in photos from the Virtual 
March for Change to commemorate the 1963 
March on Washington, DC, US. 
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Why it matters
Employment and workplaces are 
changing due to lasting impacts 
from the pandemic, shifting worker 
expectations and technological 
advances. Investments in our 
workforce support society more 
broadly, as we develop the 
workforce of tomorrow to push 
the boundaries of science and 
continue to deliver life-changing 
medicines for patients.  
As an innovation-based company, the continual 
development of our workforce is imperative for 
performance and retention, and growth of our 
organisation. We aim to prepare for and adapt 
to disruptive workplace and workforce changes 
by implementing responsible development 
practices that enable our workforce to reach their 
full potential. This makes business sense, as the 
future of our company depends on our people. 
 Description
Companyeffortstofosteralife-longlearning
organisation, form the best teams, facilitate 
agile ways of working, upskill and reskill current 
employees, and engage and prepare all employees 
for digitalisation and automation.  
 Approach
We strive to provide the work environment and 
opportunities our 75,600 employees need to thrive. 
Weworktoinstilinouremployeestheconfidence
to challenge convention and explore new 
possibilities. We invest in our workforce through 
professional and technical training, and we enhance 
this through leadership, mentorship and job-rotation 
programmes. Our People strategy focuses on:
• Life-long learning — We recognise that to 
thrive in a complex and ever-changing world, it is 
imperative for us to unlock the potential in every 
one of our employees. We provide a variety of 
learning experiences to support employees at 
differentstagesoftheirjourneyatAstraZeneca
• Upskilling in critical capabilities — We identify 
and prioritise critical capabilities across our 
organisation that are needed to drive our 
company strategy and meet the challenges 
of the future
• Enterprise leadership and talent — We believe 
every employee has potential. We focus on 
identifying succession candidates for critical roles 
and capabilities, and accelerating readiness and 
career development for all employees
Our focus on Inclusion and diversity weaves through 
theseefforts.
 Governance 
Our approach is governed by our EVP, Human 
Resources, who reports to the CEO. On a biannual 
basis, the SET and Board are provided with a 
comprehensive overview of the AstraZeneca 
workforce, covering a wide range of metrics 
and measures. The SET is also provided with 
a quarterly summary of key workforce metrics.
 Key targets and progress
Talent and workforce evolution
2025 target
Build a strong learning 
and development culture 
by promoting growth 
opportunities at all levels 
of our organisation 
and ensuring a strong 




84% of employee survey 
respondents feel there 
is opportunity for growth 
and development, up 
from 83% in 2019.
2025 target
Ensure AstraZeneca 
has a highly-engaged 
workforce and is viewed 





89% of employee survey 
respondents feel that 
AstraZeneca is a Great 
Place to Work, up from 
86% in 2019.
Our work contributes to this 
Sustainable Development Goal:
SDG 17 | Partnership for the goals
    See Sustainability Data Summary 
for full metrics and methodology.
We work to instil 
in our employees the 
confidence to challenge 
convention and explore 
new possibilities.
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Global platform makes learning 
more accessible
In 2020, we launched Degreed — a new global 
online learning platform. Degreed is a single point 
of access to a world of learning. The new platform 
is personalised — enabling our workforce to 
guide their own learning, receive personal content 
recommendations and collaborate with colleagues. 
Degreedoffersaccesstoavastrangeofhigh-
quality resources — more than 20,000 multi-lingual 
on-demand videos, articles, books, podcasts 
and courses from world-class partners such as 
LinkedIn Learning and MindTools — alongside 
our own internal content. We have also launched 
business area learning academies, supporting our 
people in developing skills associated with digital 
and data, procurement, innovative value strategies, 
and human resources.
• 67% of employees registered 
• 500,000 learning modules completed 
“ We’re delighted to be opening up this 
dynamic and digital gateway for learning to 
everyone at a time when the need for agility, 
innovation and new perspectives is so important 
and while so many are working remotely. 
Degreed puts you in the driving seat, with the 
power to develop the skills you want and to 
shape the future you aspire to. We’re launching 
today with thousands of great resources, and 
creating a globally connected community of 
AstraZeneca learners.”
—  Marc Howells, VP Talent & Development
Transforming 
performance development
Performance development is part of our 
commitment to our people and plays an important 
role in creating a culture of growth. Inspired by 
employee feedback, a new system for performance 
development was introduced in 2020. We have 
invested in over 500 virtual workshops and a 
suite of online toolkits to upskill and build new 
coaching and feed forward capabilities for our 
12,000 line managers. The new system involves a 
shift away from performance ratings and rankings 
towards ongoing development and continuous 
improvement, including: 
Coaching — quarterly check-ins with managers 
to share experiences, ideas and points of view 
to arrive at agreed outcomes
Feeding forward — forward focused 
conversations to support development and 
growth for the future
Finding ways for employees to stretch — 
in what they do or how they do it
New learning experiences
We know that to be successful in a complex 
world we must become a learning organisation, 
ready and equipped to embrace the challenges 
that lie ahead. We continually expand our 
learning and development portfolio to support 
ouremployeesatdifferentstagesoftheirjourney
with us. Six new development programmes were 
launched in 2020, including: 
• Accelerate! — A face-to-face, online and 
immersive experience designed to enable 
leadership talent from our emerging and growth 
markets to execute their local and regional 
business strategy while developing their 
enterprise capability
• Leadership Labs — A development experience 
for career level E/F managers that supports 
participants to lead their teams and functions to 
deliver business performance during rapid growth 
by focusing on building core leadership skills that 
are highly relevant for ‘the now’ 
• Team effectiveness — A suite of learning 
experiencestobuildteameffectivenessin
support of our strategy and Values, covering 
topics such as respecting diversity and 
building trust
Talent and workforce evolution continued
Challenges
Aspects of Talent and workforce evolution are 
captured in our enterprise risk management 
process. 'Failure to attract, develop, engage 
and retain a diverse, talented and capable 
workforce' is a principle risk. This risk has 
the potential to have a material impact on our 
business or results of operations, as described 
in our Annual Report. 
Sustainability in action
 Highlights
Internal peer-to-peer recognition platform 
CatAlyZe is an online platform that enables all 
employees, regardless of role, geography or level, 
to highlight exceptional work based on the way we 
demonstrate our Values and behaviours. It is used to 
celebrate the contributions of individuals and teams, 
and show appreciation in real time.  
Developing our talent pipeline through STEM
The global Generation Health: How Science Powers Us 
programme was developed to elevate and explain the 
science underpinning the prevention and treatment of 
disease by providing hands-on STEM learning activities. 
Students age 11–13 investigated both preventative 
measures and innovative solutions to key health 
concerns in the areas of oncology, cardiovascular and 
respiratory disease.
Generation Health programming also includes 
Drop Anywhere Labs,whicharecustom-outfitted
STEMlearningspacesbuiltfrommodifiedshipping
containers. These easy to transport, inexpensive labs 
provide a range of career and skills education for 
youngschoolstudents,aswellasflexiblein-classroom





shifts away from performance 
ratings and rankings towards 
ongoing development and 
continuous improvement.
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Why it matters
To continue to deliver medicines 
to patients, we have to foster an 
environment where people feel 
safe, energised and inspired. 
This is only possible through a 
holistic approach that integrates 
mental, physical and financial 
health for a complete sense of 
wellbeing. The resources we put 
into supporting the health and 
safety of our workforce are an 
investment in society and the 
long-term health of economies.   
Wellbeing is associated with numerous health, 
employment,familyandeconomicbenefits.1 
Fostering wellbeing and promoting a safe 
environment, free of injuries, is not only the right 
thing to do but can also have positive impacts on 
business productivity and costs. Depression and 
anxietyhaveasignificanteconomicimpact,with
an estimated cost to the global economy of 
US$1 trillion per year in lost productivity.2 
 Description
Companyeffortstocreateahealthyandsafe
working environment are conducive to a workforce 
thriving and maintaining good work–life integration. 
Thisincludeseffortstolimitsafetyhazardsfor
employees through proper design, engineering 
and preventative maintenance, and embedding 
a safety, health and environment (SHE) culture 
across the organisation.  
 Approach
We strive to ensure our workforce has the resources 
not only to deal with, but to thrive in challenging 
circumstances. We take a holistic approach, 
consideringphysical,financialandmentalwellbeing
dimensions at work, in transit and at home:  
Physical wellbeing — supporting all aspects of 
physical health, e.g. exercising and managing any 
conditions or diseases
Mental wellbeing — feeling positive, building 
resilience, achieving balance and a strong sense 
of community
Financial wellbeing—managingfinances
today while preparing for the future
We investigate safety incidents to understand root 
causes and make changes to prevent reoccurrence. 
Learnings are reviewed by a panel of subject matter 
experts then distributed globally. Our global SHE 
standards and procedures establish mandatory 
requirements in key risk areas. 
Our Code of Ethics includes elements relating to 
workforce wellbeing and safety: we promote and 
maintainasafe,healthy,secureworkenvironment;
weuseeffectiveSHEmanagementsystemsto
identify and manage risk and maintain strong 
SHEperformance;weonlyworkwithotherswho
embrace SHE standards consistent with ours.
Our 2020 Code of Ethics global mandatory 
training focused on wellbeing during the pandemic, 
including personal examples of how our employees 
have built resilience and grown during challenging 
times. The training also included an example of how 
to handle a safety incident by applying Human and 
Organisational Performance (HOP) principles.
 Governance 
Workforce wellbeing is governed by our EVP, 
Human Resources. In 2020, a new Global Director 
of Wellbeing was appointed to further develop our 
strategy,enablingashiftfromtraditionalbenefits
to broader employee wellbeing. Safety is governed 
by our EVP, Sustainability and Chief Compliance 
Officer.Weuseassuranceprogrammestomonitor
and manage performance. Some sites seek external 
review and we achieved ISO 45001 (occupational 
health)certificationatour:Macclesfield,UK,
Södertälje,Sweden;andTaipei,Taiwansites,
accounting for more than 8,000 of our employees. 
 Key targets and progress 
Workforce wellbeing and safety
    See Sustainability Data Summary 
for full metrics and methodology.
Our work contributes to these 
Sustainable Development Goals:
SDG 3 | Good health and wellbeing 
SDG 8 | Decent work and economic growth 
SDG 17 | Partnership for the goals
$1 invested 
to treat common mental 
health issues = 
$4 return 
in improved health and 
productivity.2 
Employees shared 
examples of resilience and 
growth for the 2020 Code 
of Ethics training.
2025 target
Safety: 75% reduction 





The injury rate has 
decreased, bringing 
our total decrease 
since 2015 to 64%.
2025 target
Driver safety: 
55% reduction in 
collisions per million 





The collision rate has 
decreased, bringing our 
total decrease since 
2015 to 46%. 
2025 target
Healthy workforce: 
80% of sites/marketing 
companies have all four 
Essential Health Activities 
in place: healthy eating 







86% of sites promote 
the four Essential Health 
Activities.3 This target 
was achieved in 2020. 
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Workforce wellbeing and safety continued
Challenges
Some Workforce wellbeing and safety risks 
are included in the risk 'Failure to adhere to 
applicable laws, rules and regulations'. This 
risk references occupational health and safety 
regulation and has the potential to have a 
material impact on our business or results of 
operations, as described in our Annual Report. 
Sustainability in action
Workforce mental health 
in times of COVID-19 
Our workforce has faced a number of new and 
exacerbated challenges during the pandemic 
and we are proud of the mental wellbeing support 
wehaveoffered.
• Wellbeing guidance resources were published 
not only for AstraZeneca, but also for public use. 
We shared toolkits for employees and leaders 
with advice on how to navigate COVID-19 and 
develop new skills for the future. These toolkits 
included details on building resilience and 
positivity, focusing on physical wellbeing through 
movement and recovery, mental wellbeing 
through mindset and social contact, and tips 
forfinancialwellbeing
• Flexible working options were provided, 
ensuring that employees made work 
arrangements that took childcare and 
eldercare responsibilities into account as well 
as underlying health conditions or the use of 
publictransportation.Thisflexibilitycontinued
tobeacoreofferingforouremployeesaswe
encountered the various phases of return to work 
• Employee assistance programmes were 
launched in markets like Latin America to provide 
employees access to mental wellbeing resources. 
In addition, our largest sites in the US have 
on-site mental health professionals that 
employeescanspeakwithconfidentially
• Manager training was deployed to emphasise 
the important role managers play in supporting 
their own mental health and that of their teams 
during and beyond the pandemic. The course 
helpsparticipantsfeelmoreconfidentin
spotting signs and supporting someone in need 
by training them on how to point colleagues 
towards the right mental health care options. 
Thiscoursewasofferedinadditiontogeneral
mental health training for managers
Human and Organisational 
Performance (HOP) in action
We are integrating HOP — a science-based 
approach to understanding how and why 
people make mistakes and what organisational 
improvements can be made — into our business. 
We applied HOP to a learning team event at our 
facility in Coppell, Texas, US. An employee, who 
was using a power washer to clean equipment, 
was injured when a high-pressure water stream 
contacted his hand. This was categorised as 
a potential serious injury or fatality (P-SIF). 
Traditional safety incident investigations may 
tell us what happened but learning teams tell us 
what is happening. A learning team helps identify 
differencesbetweenthewayweplannedthework
(work-as-imagined) and the way that the work 
actually happens (work-as-done), providing valuable 
information that can be fed back into our processes 
to ensure learning and improvement. Based on the 
learning team output, the site process in Coppell 
was adjusted. 
Creating a culture of safety 
around warehouses
In 2020, we started a serious injury or fatality 
(SIF) prevention programme in our warehouses. 
We reviewed our P-SIF events and found more 
effortswereneeded,inparticularforforklifttrucks
and racking systems. We worked with warehouse 
managers to share best practices across the sites 
and conduct training scenarios. We also developed 
a warehouse minimum standard, which will be a 
focus area for our audit programme. We believe 
thecombinedeffortswillreduceourwarehouse
incidents and thereby protect our workforce, 
assets and facilities. 
 Highlights
AstraZeneca most active healthcare 
company in global wellbeing challenge 
AstraZeneca employees from 
38 countries participated in the 100-day 
Virgin Pulse Global Challenge (VPGC)® 2020. 
The online programme includes physical and 
psychological health risk assessments, step 
tracking, and modules for nutrition, sleep and mental 
wellbeing. A team from the US ranked 7th out of 
262 companies taking part in the challenge. 
Gaithersburg site wins wellness awards
• Silver award for The Healthiest Maryland 
Businesses (HMB) Wellness at Work awards 
programme — recognises businesses that have 
established worksite wellness practices and 
workplace health improvement plans.
• The Alliance for Workplace Excellence Health 
& Wellness Seal of Approval — recognises 
employers that demonstrate an outstanding 
commitment to their employees’ health and 
wellness and lead the way implementing 
innovative programmes. Wellness programmes 
are evaluated based on education and awareness, 
health and wellness programmes, and health 






Links within this toolkit take you to sites maintained by 
third parties who are solely responsible for their content. 
AstraZeneca provides this toolkit as a service to website 
visitors. AstraZeneca is not responsible for the privacy 
policy of any third party websites. We encourage you to 
read the privacy policy of every website you visit
Top tips and resources to help you 
develop the mindset and behaviours 
to navigate through uncertainty, 
maintain high performance and 
develop new skills for the future Employee toolkit emphasising the importance of mental 
health, including advice on how to navigate COVID-19 
and develop new skills for the future.
We published wellbeing 
resources not only for 
AstraZeneca, but also 
for public use. 
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Why it matters
A large supply chain amplifies 
business impacts on people 
and the planet, both the 
positives and negatives. 
We are accountable for 
understanding the impact of 
our entire supply chain and 
seek to make a positive impact 
on workforces, communities 
and the environment.  
We interact with an extensive network of 
suppliers globally, and this reach gives us 
the opportunity — and responsibility — to 
promote practices with our suppliers that 
are socially and environmentally sustainable. 
Our business success depends on a resilient, 
transparent and inclusive supply chain that 
supports responsible sourcing, development 
and manufacturing. Embedding sustainability 
throughout our supply chain through 
collaboration with our suppliers increases 
business value for all. 
 Description
Company processes for sourcing external 
resources, including building robust supplier 
relationships with considerations of suppliers’ 
environmental and social practices. 
 Approach
We support suppliers by:
Offeringopportunitiestobuildtheirown
sustainability knowledge and capabilities 
 Holding them to high standards
Throughout the lifetime of our 
relationship with each supplier, we seek 
to ensure that their conduct matches 
the expectations outlined in our 
Global Standard Expectations of Third Parties. 
We aim to work only with suppliers whose 
values are consistent with our own and 
who are committed to developing inclusive, 
resilient and transparent businesses.
Inclusive — Suppliers create value 
for all employees and people within 
their communities
Resilient — Suppliers’ operations 
are adaptive to climate change 
and resource scarcity
Transparent — Sustainability 
practices across our worldwide 
supplychainarereadilyverified
Our Sustainability Partner Guide and Framework 
for our critical manufacturing partners 
assesses and rewards sustainability 
performance.
We have prioritised our sustainability approach 
on categories of suppliers in our product 
supply chain, including active pharmaceutical 
ingredients (APIs), formulation and packaging, 




75% of all critical manufacturing 
partnersitesarerated‘bronze’
or better in our Sustainability 




64% (67 of 105 supplier sites) 




Launch supplier diversity 
programmes in 10 new countries 




Programme launched in two 
more countries – South Africa 
and United Kingdom, bringing 




Embed sustainability into 
our end-to-end procurement 





• Global Standard 
updated to incorporate 
sustainability priorities
• Sustainability included as 
a required component of 
all category strategies3  
• Sustainability assessment 
platform EcoVadis piloted 
across multiple categories, 
planned to be implemented 
enterprise wide
Our suppliers contribute to a number of other metrics and initiatives, 
such as Ambition Zero Carbon and safe API discharges.
Our work contributes to these 
Sustainable Development Goals:
SDG 8 | Decent work and economic growth 
SDG 12 | Responsible consumption and production 
SDG 17 | Partnership for the goals
    See Sustainability Data Summary 
for full metrics and methodology.Supply chain 
colleagues in Japan.
 Key targets and progress
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Responsible supply chain 
continued
 Governance 
The Global Operations and Global Sustainability 
functions have a shared responsibility to execute 
our Responsible supply chain strategy. Our EVP, 
Operations and IT, who reports directly to the CEO, 
has oversight of our supply chain, including our 
internal and external manufacturing network. 
In 2020, we launched a new Operations 
Sustainability Council. This is chaired by our 
Vice-President of Global SHE and Operations 
Sustainability and includes around 20 business 
leaders from across Operations and Global 
Sustainability who are key in supporting the 
delivery of our Responsible supply chain 
strategy, along with other sustainability goals 
within Operations. The Council also works 
closelywithourChiefProcurementOfficer
who oversees the implementation of our 
Positive Sourcing Programme.
" Our new Operations Sustainability Council 
is integrating sustainable practices across all 
areas within our supply and manufacturing 
organisation that raise the bar on resilience and 
transparency, ensuring delivery of programmes 
that further all our Operations goals."
—  Vice-President of Global SHE and 
Operations Sustainability
Sustainability in action
Operations Sustainability Council members. 
Promoting responsible sourcing 
Our Positive Sourcing Programme delivers value to our business and society by embedding 
sustainability into end-to-end procurement processes. We embed responsible sourcing practices by 
working with suppliers to support their sustainability journeys, innovate together on challenges, and 
promote supplier diversity. 
Supporting suppliers' 
sustainability journeys
We support our suppliers to establish a foundation 
insustainability,scaletheireffortsthrough
collaborative projects, and deliver impact 
for a healthier world. This not only enhances 
supplier capacity, but also helps us achieve our 
sustainability ambitions. We enhanced our 
third-party expectations and request for proposal 
(RFP) guidance to cover sustainability topics such 
as human rights and labour, health and safety, 
environment and supplier diversity.
Innovating together on challenges
We committed to launching our next-generation 
inhalerwithnear-zeroglobalwarmingpotential
(GWP) propellants by 2025 as part of 
Ambition Zero Carbon. We expect that the 
propellant used in the next generation pressurised 
metered-dose inhalers (pMDI) will have a GWP 
that is 90–99% lower than propellants used in 
existing pMDIs.
Promoting supplier diversity 
We support an inclusive and diverse supply 
chain through our supplier diversity programme. 
In 2020, we expanded to South Africa and the 
United Kingdom, making the programme active 
in four countries, including the United States and 
Brazil.Wehostedvirtualevents,withourChief
ProcurementOfficeractivelyparticipatingand
sharing his commitment to AstraZeneca’s supplier 
diversityefforts.Theseeventsincludedexternal
partners, such as WeConnect International, 
Minority Supplier Development UK (MSDUK) and 
SocialEnterpriseUK,whosupportourefforts.
The spotlight on the Black Lives Matter movement 
sparked important conversations about eliminating 
racism from society. We asked our partners to 
jointheeffortstoaddressinequities.OurChief
ProcurementOfficersentalettertohundreds
of key suppliers to explore opportunities to 
broaden inclusion in our business, workforce 
and communities. 
Advancing sustainability maturity 
across internal manufacturing
Our supply chain is more than just our 
external  partners — it is made up of 29 internal 
manufacturinglocations.Inanefforttofurther
promote sustainability across our manufacturing 
sites, we developed a common sustainability 
maturity framework. This framework outlines 
sustainability excellence over four maturity levels, 
from foundational to ideal state. It provides 
a roadmap of practices aimed at enabling 
sustainable practices and performance. We piloted 
this maturity model across seven sites in 2020 
and plan to extend this approach as we embed 
responsible supply chain principles into our lean 
maturity review process.
Transforming our supply chain 
to achieve Ambition Zero Carbon
In 2020, we announced Ambition Zero Carbon. 
This includes a 2030 target to have a carbon 
negative value chain. With 97% of our footprint in 
our value chain (including logistics and purchased 
goods and services), reaching our 2030 target will 
require unprecedented coordination throughout 
our supply chain planning processes. Through 
our new Operations strategy, we have embedded 
sustainability in both our product and supply chain 
design approach, including additional life cycle 
assessments across our portfolio. See more in 
Product environmental stewardship.
Our supplier diversity 
programme is active 
in Brazil, South Africa, 
the UK and US.
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Sourcing raw materials from nature 
Our medicines are created from many raw 
materials that come from nature and from 
some areas in the world with environmental 
and human rights issues. We recognise the 
importance of understanding the sustainability 
impacts of these sourcing activities. In 2020, 
we began to build a framework to drive change 
for materials of natural origin — including 
agriculture,aquaculture,forestry,fishery,
and mining — used in our supply chain.
Through the Pharmaceutical Supply Chain 
Initiative (PSCI), we worked to understand 
our collective human rights and environmental 
impacts as a pharmaceutical industry. 
This research informed PSCI members of 
existingcertificationschemesfromreputable 
non-governmental organisations to help ensure 
that our purchases come from well-managed 
and responsible sources based on supply 
chaintransparencyandcredibleverification.
As a result of this engagement, we set a target 
to have sustainability action plans in place 
for 12 key raw materials by 2025.
Responsible supply chain continued
Sustainability in action
Challenges
Aspects of Responsible supply chain are 
implicated in at least three areas of our 
enterprise risk management process, as 
described in our Annual Report. The following 
are AstraZeneca principal risks with the 
potential to have a material impact on our 
business or results of operations: 'Failure or 
delay in the delivery of our pipeline or launch 
ofnewproducts';'Failuretomaintainsupplyof
compliant,qualityproducts';and'Relianceon
third party goods and services'.
 Highlights
CDP Supplier Engagement Leader Board 
AstraZeneca was among the top 7% of companies 
assessed by CDP to be awarded a position on the 
leader board. We are recognised for our actions to 
lower climate-related risks in the supply chain and 
working with our suppliers to reduce their emissions.
Recognition
• 2020 HubZone Prime Contractor National Award 
for supporting US small businesses in economically 
underutilised areas
• 2020 Corporate Done Deal Award by Women 
Business Enterprise Center for achieving the 
highestcertifiedwomen-ownedbusinessspend 
in the US PA-DE-NJ region
• 2020 Corporate Champion Award by Women 
PresidentsEducationalOrganization for having 
highest spend with women-owned businesses 
in the US Washington, DC region
AstraZeneca’s action plan includes the following 
materials in our approach:
Key:
 Raw materials
  Our approach






  Forest Stewardship 
Council Certification
 Aluminium
  Aluminium 
Stewardship Initiative
 Timber
  Forest Stewardship 
Council
  Sustainable Forestry 
Initiative




  Roundtable on  
Sustainable Palm Oil
 Fish Oil
  Marine Stewardship 
Council Certification
 Shellac
  Human rights impact 
assessments
 Talc
  Human rights impact 
assessments
 Carnauba Wax




  Forest Stewardship 
Council Certification
 Sugar
   Bonsucro  
Certification
 Castor Oil
  Sustainable Castor 
Association 
SuCCESSCode
  Tin, Tungsten, 
Tantalum, Gold 
and other minerals
  Minerals Traceability 
Programme
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Why it matters
All human beings have basic 
rights and freedoms — such as 
the right to health, bodily integrity 
such as freedom from slavery, 
and civil liberties such as the 
right to privacy. For societies and 
economies to thrive, it is important 
that human rights are respected.   
As a business, upholding human rights is 
foundational to our ability to retain talent, 
our social acceptance to operate and the 
delivery of other sustainability focus areas 
such as Disease prevention and treatment, 
Ethical business culture, Inclusion and diversity, 




to all human beings. These rights are 
interrelated, as stated in the 
Universal Declaration of Human Rights. 
This includes the rights to health, 
non-discrimination, humane treatment 
and data privacy. 
 Approach
As a healthcare company, we believe health is a 
human right and therefore enabling access to our 
medicines is vital. Beyond our core business of 
health, it is our responsibility to understand how we 
are contributing to or hindering human rights due 
to our operations. This includes taking action on 
both basic and emerging issues such as modern 
slavery, workforce treatment, labour rights and data 
privacy. We aim to prevent human rights violations 
by proactively identifying any issues in our business 
and responding promptly with appropriate action.
As signatories to the UN Global Compact 
(UNGC) for the past 10 years, we commit to the 
Guiding Principles to respect human rights by 
acting with due diligence to avoid infringing on 
human rights and to address negative impacts. 
We are also committed to the International 
LabourOrganization(ILO)standards on child 
labour and minimum working age.
We have internal policies, statements and 
procedures that build upon these external 
commitments:
  Human Rights Statement; 
Modern Slavery Act Statement; 
ConflictMineralsStatement; 
Code of Ethics; 
Data Privacy Standard. 
" We have ensured that the UNGC and its 
Ten Principles have become part of our strategy, 
culture and day-to-day operations, and they will 
remain vitally important in the years ahead."
—  Pascal Soriot, AstraZeneca CEO 
in a recommitment letter to the UNGC
We address discrimination dimensions 
of human rights, including setting an 
enterprise-wide ambition in 2020 to ensure 
racial equity in our workplace and access to 
our medicines, in our clinical trials and beyond. 
See more actions in Inclusion and diversity. 
 Governance 
Accountability for human rights is held by all SET 
members who each report to the CEO. Our Board 
of Director's Audit Committee annually reviews our 
modern slavery approach and the company's risk 
management strategy. This includes risk awareness 
and education, and control enhancements to 
support assurance that the risk of modern slavery 
andhumantraffickingiseliminated,tothefullest
extent practicable, from AstraZeneca’s supply 
chain. Our Operations Sustainability Council works 
to develop new approaches to understand, monitor 
andmitigateidentifiedhumanrightsrisks.
 Key target and progress
Human rights
2020 target
Improve the AstraZeneca 
global biannual human 
rights survey by using 
Fair Wage Network data 
to more robustly assess 
our performance against 




We enhanced the 2020 
survey with terminology 
definitions,risk
awareness questions 
on modern slavery and 
humantraffickinganda
supplemental appendix 
with expanded indicators. 
This facilitated clarity of 
the inquiry and ability to 
identifyspecificgaps.
We used independently 
produced data from the 
Fair Wage database 
in our 2020 survey to 
measure against the 
real earnings of all our 
employees, in which 
we performed well. 
Our work contributes to this 
Sustainable Development Goal:
SDG 17 | Partnership for the goals
    See Sustainability Data Summary 
for full metrics and methodology.
AstraZeneca’s Human 
Rights Statement applies 
to our employees, 
extended workforce, 
supply chain, patients 
and community members.
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Human rights continued
Human rights survey
We conduct an internal assessment of our human 
rights practices every two years. In 2020, we 
completedourfifthglobalhumanrightslabour
review which focuses on the International Labour 
Organization's(ILO)corethemes,including
freedom of association and collective bargaining, 
child labour, discrimination, working hours and 
wages. The digital survey was distributed to the 
Human Resources representative at more than 
100 AstraZeneca sites worldwide. We enhanced 
thesurveybyaddingterminologydefinitionsand
three new indicators covering local leadership's 
awareness of human rights considerations including 
modern slavery, risk assessment of temporary 
labour agencies, and mitigation resources.
Where local gaps to ILO minimum standards are 
identified,suchasmaternityleaveorgrievance
procedures, we put in place plans to close those 
gaps where allowed by relevant national legislation. 
Based on the last report, we have increased paid 
maternity leave up to the minimum standard of 
14 paid weeks in Mexico, Malaysia, Thailand, 
Saudi Arabia and Egypt. 
Identifying human rights impacts in 
our supply chain
In 2020, we participated in a Pharmaceutical 
Supply Chain Initiative (PSCI) project to map human 
rights impacts in our supply chain for 12 key raw 
materials. PSCI analysed risk areas including labour 
rights, land rights, child labour, forced labour, 
gender rights and the environment. As a result of 
this project, AstraZeneca and other pharmaceutical 
companies now have a common understanding of 
high-risk activities, such as harvesting, cultivation, 
and mining, and corresponding mitigation strategies 
in deeper tiers of the supply chain. This information 
is being used to create sustainability action plans 
for 12 key raw materials, such as carnauba wax. 
See more in Responsible supply chain.  
Progressing work on the right to 
data privacy 
Personal data privacy is a human right. Our 
information is one of our greatest assets. It includes 
everything that we create and store during the 
courseofourbusinessactivities,anditflows
through everything we do: our science, the way 
that we do business, and our ability to deliver 
life-changing medicines. 
We conduct Privacy Impact Assessments (PIAs) 
for personal data processes which go beyond 
what is legally required. In 2020, we conducted 
1,884 PIAs, up from 1,394 in 2019. We also 
measure the number of data subject requests we 
receive to monitor compliance with Data Subject 
Rights requirements. In 2020, privacy concerns 
increased as more of the AstraZeneca workforce 
was engaging virtually due to the pandemic. As 
part of our work on enhancements to manage and 
protect our data and information, we have updated 
our Information Incident Form and are introducing 
a new Information Incident Module to improve 
the user experience. In addition, we introduced 
anautomatedroutingandnotificationprocess
to ensure reported Information Incidents are 
investigated by the right people at the right time.
 Highlights
Partnerships to support rights holders
• Workforce: Slave-Free Alliance of Hope for 
Justice—thefirstlifesciencesindustrymember
• Suppliers and partners: PSCI Human Rights 
and Labour group
• For patients: International Association of Privacy 
Professionals, the Data Protection Working Group 
of the European Federation of Pharmaceutical 
Industries and Associations and Data Protection 
Legal for the biopharmaceutical sector
Modern slavery and human 
trafficking training
We provide training that aligns our day-to-day 
practices with our 'Speak Up' culture of identifying, 
preventing and reporting concerns. In 2020, 
we launched a modern day slavery training for 
employees and third-parties  
Challenges
Aspects of Human rights are implicated in 
our risk 'Failure to adhere to applicable laws, 
rules and regulations' as described in our 
Annual Report. Compliance with human rights 
regulations including, but not limited to, the 
ModernSlaveryActarespecificallynoted
within this risk. The risk ‘Failure to collect and 
manage data in line with legal and regulatory 
requirements and strategic objectives’ 
captures risk associated with evolving 
data privacy legislation.
Through engagements with external 
regulators and experts we have validated 
that our highest Modern Slavery Act risk 
activities are construction, sourcing of human 
biological samples, electronic components 
and agricultural ingredients that are used 
to manufacture our products, temporary 
resources, recruitment, facilities, logistics 
and hotels.
Sustainability in action
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Footnotes
2020 performance highlights
1  Includes four Access to healthcare programmes: Healthy Heart Africa, Healthy Lung, Phakamisa 
and Young Health Programme
2  Scope is 48 APIs for which data is available to calculate safe API discharge limits and based on 
2019 manufacture. 
Contribution to the SDGs
1  We also consider SDGs where we have additional or secondary impact. These include SDG 6 - 
Clean water and sanitation and SDG 15 - Life on land. Our impact on these SDGs is reflected in 










10  Includes four Access to healthcare programmes: Healthy Heart Africa, Healthy Lung, Phakamisa 
and Young Health Programme.
11  Select United Nations-related engagements shown. This is a sub-set of AstraZeneca's 
partnerships for the goals.
12  Scope is 48 APIs for which data is available to calculate safe API discharge limits and based on 
2019 manufacture.
Access to healthcare
1  Includes four Access to healthcare programmes: Healthy Heart Africa, Healthy Lung, Phakamisa 
and Young Health Programme.









6  https://www.diabetesatlas.org/upload/resources material/20200302_133351_IDFATLAS9e-final-
web.pdf
7 https://pubmed.ncbi.nlm.nih.gov/32363737/



















1  Since 2019, we have refined our approach from innovative value strategies (IVS) to value-based 
agreements (VBA).
Environmental protection






4  Additional parts of our EMS include: Clear responsibilities for leaders and line managers; Global 
targets implemented locally at sites in partnership across functions; Mandatory training aligned to 









4  0.1% of imported electricity could not be matched to renewables due to the lack of credible energy 
attribute certificate systems in two site locations: Argentina and Ukraine.
Pharmaceuticals in the environment
1  Scope is 48 APIs for which data is available to calculate safe API discharge limits and based on 
2019 manufacture.
2  Maynard et al., 2020a. Abstract 4.09P.2. Available at: via https://dublin.setac.org/wp-content/
uploads/2020/04/SETAC-SciCon-Abstract-book_v2.pdf
3  Maynard et al., 2020b. Abstract 4.09PC.2. Available at: https://dublin.setac.org/wp-content/
uploads/2020/04/SETAC-SciCon-Abstract-book_v2.pdf




















Workforce wellbeing and safety
1  https://www.cdc.gov/hrqol/wellbeing.htm#
2 https://www.who.int/mental_health/in_the_workplace/en/
3 For sites that did not respond to the 2020 survey, the responses from previous years were used.
Responsible supply chain
1  Target applies to suppliers in the Active Pharmaceutical Ingredient (API) and Formulation and 
Packaging (F&P), and Device categories. All suppliers are in scope for the framework; however, 
suppliers are only in scope for PSCI environmental sustainability assessments if they cover >90% 
of our spend per the Sustainability Partner Guide and Framework.
2  Updated target: The foundation of our Positive Sourcing Programme includes monitoring business 
risk and sustainability practices. In 2020, we began a transformation of our 3PRM process to 
include sustainability criteria. Our former 3PRM target has evolved with our Positive Sourcing 
Programme targets.
3  Categories refer to an area where procurement focuses, for example; primary packaging, 
excipients, process chemicals, media, clinical trials. A category strategy sets the vision of where a 
category will be in the short to medium term.
Notices
Cautionary statements regarding forward-looking statements
In order, among other things, to utilise the ‘safe harbor’ provisions of the US Private 
Securities Litigation Reform Act of 1995 and the UK Companies Act 2006, we are 
providing the following cautionary statement: 
This Sustainability Report contains certain forward-looking statements with respect 
totheoperations,performanceandfinancialconditionoftheGroup.Forward-looking
statements are statements relating to the future which are based on information 
available at the time such statements are made, including information relating to risks 
and uncertainties. Although we believe that the forward-looking statements in this 




at the date of the preparation of this Sustainability Report and the Company undertakes 
no obligation to update these forward-looking statements. We identify the forward-
looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, ‘intends’, 
‘aims’, ‘aspires’, ‘seeks’, 'estimate', 'will', 'project', 'plan', 'target' and similar expressions 
insuchstatements.Importantfactorsthatcouldcauseactualresultstodiffermaterially
from those contained in forward-looking statements, certain of which are beyond our 
control,include,amongotherthings,thosefactorsidentifiedasrisksandchallenges.
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